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ABSTRACT 
 
 
 The ATP-binding cassette (ABC) transporters play an important role as a barrier 
to protect cells from the accumulation of toxic xenobiotics and metabolites due to their 
ability to translocate a wide array of compounds across lipid bilayers. However, many 
ABC transporters, especially the ones localized in the intracellular organelles, are 
involved in critical biological processes such as antigen presentation. The core unit of 
ABC transporters contains two functional domains: the membrane spanning domain 
(MSD) and the nucleotide binding domain. The full transporters contain two of these 
units in tandem in a single polypeptide, whereas the half transporters only contain one 
and must homo- or hetero-dimerize in order to exert their functions. A half transporter 
ABCB6 has been shown to localize in mitochondria and suggested to play a role in iron 
homeostasis; however, its function remained elusive. Therefore, we aimed to characterize 
several aspects of ABCB6: identification of substrates, physiological role, transport 
mechanism and intracellular trafficking. In this study, we show that ABCB6 is a 
homodimeric mitochondrial outer membrane protein. Furthermore, we identified ABCB6 
as a porphyrin transporter that facilitates heme biosynthesis, in which the intermediates 
must be shuttled between mitochondria and the cytosol. Translocation of substrates by 
ABC transporters occurs in an ATP-dependent manner, although the role of ATP binding 
and hydrolysis in the transport process remains controversial. Taking advantage of its 
ability to bind hemin conjugated to agarose beads, we demonstrate that the ATP binding 
at the NBD is sufficient to induce a conformational change to a low affinity state in 
ABCB6. In an attempt to understand how ABCB6 trafficks intracellularly, we identified a 
post-translational modification that indicates ER to Golgi trafficking during its 
maturation. Moreover, we identified a novel N-terminal disulfide bond that plays an 
important role in the ER exit of ABCB6. This disulfide bond motif is found in other ABC 
family members and the loss of the conserved cysteine residue in ABCC8/SUR1 is the 
genetic basis for hyperinsulinemic hypoglycemia. Because ER redox status appears to 
play an important role in the trafficking of these proteins, expression patterns of ABC 
transporters may be altered in pathophysiological conditions such as diabetes where 
microsomal redox status is shifted. 
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CHAPTER 1.  INTRODUCTION 
 
 
1.1. Historic Overview: Discovery of P-glycoprotein and ABC Protein Superfamily  
 
 ... in resistant cells there is an outward flow of daunomycin which is against an 
electrochemical gradient, carrier mediated, and dependent on the energy metabolism. 
Dano, K., Active outward transport of daunomycin in resistant Ehrlich ascites 
tumor cell, p. 480 [1]. 
 
The adenosine triphosphate (ATP)-binding cassette (ABC) transporters in the 
ABC protein superfamily translocate various molecules across lipid bilayers in an 
energy-dependent manner. Because of their wide array of substrates, genetic variations in 
ABC transporters are now known to be involved in the pathophysiology of numerous 
human disorders (Table 1.1.)[2]. ABC proteins comprise one of the largest protein 
superfamilies with 48 members identified to date in humans. The first mammalian ABC 
protein was discovered in 1976 as a 170-kDa membrane glycoprotein that was 
overexpressed in colchicine resistant cell lines [3]. These cells were cross-resistant to 
different classes of drugs, and it was speculated that this protein altered drug permeability 
at the membrane resulting in a lower accumulation of drugs in resistant cells. Thus, this 
protein was named P glycoprotein (P-gp) for glycoprotein that reduces drug permeability. 
Many had suspected early on that multidrug resistance (MDR) would be a major obstacle 
in treating complex diseases such as cancer. By 1960’s, several groups found a 
correlation between drug accumulation and drug response [4-6]; however, the uptake 
(influx) and efflux of drugs were not discriminated, and they simply speculated that the 
rate of uptake was altered in the drug resistant cells. In 1973, Dano provided definitive 
evidence of active efflux of daunomycin by measuring the steady state intracellular and 
extracellular drug accumulation in parental and daunomycin resistant cell lines [1]. Also, 
a metabolic inhibitor, β-deoxyglucose, was shown to inhibit the efflux of daunomycin. 
From these experiments, Dano concluded that “in resistant cells there is an outward flow 
of daunomycin which is against an electrochemical gradient, carrier mediated, and 
dependent on the energy metabolism” [1], which accurately predicted the function of yet 
to be identified ABC transporters.   
 
While Ling and his colleagues observed P-gp gene (~4.7 kilobases (kb)) 
amplification in different MDR mammalian cell lines and were determined to identify the 
role of P-gp in MDR [7], Roninson and colleagues identified and isolated DNA 
sequences that were commonly amplified in several MDR cell lines [8]. Of the many 
amplified DNA sequences observed, one such region, mdr, was isolated, which was 
found to contain a gene that transcribed ~5 kb mRNA [9]. Gros and the colleagues then 
went on to show that the ectopic expression of mouse mdr1 cDNA conferred MDR in 
drug-sensitive Chinese Hamster cells [10]. However, the relationship between P-gp and 
mdr was not clear at this point. Using P-gp specific antibody and cross-hybridization of 
P-gp probe and mdr1 cDNA, Ueda et al. finally showed that the mdr1 gene product is P-
gp [11]. It became clear from different approaches to identify mechanisms of MDR 
phenotypes that P-gp, the product of mdr1, was one of the key players in MDR. 
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Table 1.1. Diseases and phenotypes caused by mutations or a lack of ABC genes. 
 
 Gene Mendelian disorder/phenotype Reference 
 
 ABCA1 Tangier disease, FHDLD [12-16] 
 ABCA3 Lung Surfactant deficiency [17] 
 ABCA4 Stargards/FFM, RP, CRD [18, 19] 
 ABCA12 Lamellar and harlequin ichthyosis [20] 
 ABCB1 Ivermectin sensitivity (in collie dogs) [21, 22] 
 ABCB2 Immune deficiency [23, 24] 
 ABCB3 Immune deficiency [23, 24] 
 ABCB4 PFIC-3 [25] 
 ABCB7 XLSA/A [26] 
 ABCB11 PFIC-2 [27] 
 ABCC2 Dubin-Johnson syndrome [28] 
 ABCC6 Pseudoxanthoma elasticum [29] 
 ABCC7 Cystic fibrosis [30] 
 ABCC8 FPHHI [31] 
 ABCC9 DCVT [32] 
 ABCC11 Dry ear wax [33] 
 ABCD1 ALD [34] 
 ABCG2 Porphyria (observed in mouse) [35] 
 ABCG5 Sitosterolemia [36] 
 ABCG8 Sitosterolemia [36] 
 
 
Abbreviations used are ALD, adrenoleukodystrophy; CRD, cone-rod dystrophy; DCVT, 
dilated cardiomyopathy with ventricular tachycardia; FFM, fundus flavimaculatus; 
FHDLD, familial hypoapoproteinemia; FPHHI, familial persistent hyperinsulinemic 
hypoglycemia of infancy; PFIC, progressive familial intrahepatic cholestasis; RP, retinitis 
pigmentosum 19; XLSA/A X-linked sideroblastic anemia and ataxia. 
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The clue to the function of P-gp/MDR came from findings in bacterial 
periplasmic binding protein-dependent transport systems (early name for bacterial ABC). 
A conserved nucleotide-binding fold [37], containing Walker A and B, was found in 
hisP/malK/oppD, components of different transport systems, and oppD indeed bound to 
an ATP analog [38]. These findings led to a model that these transport systems were 
energy-dependent and ATP hydrolysis at hisP/malK/oppD were responsible for a 
conformational change to transmit the information to the substrate binding component 
[38]. By using the deduced amino acid sequence of P-gp/mdr, it was shown that P-gp/mdr 
shared a high sequence homology with hisP/malK/oppD [39, 40] and hlyB [41] at the 
nucleotide-binding fold. Combined with the prediction from hydropathy plots, the 
proposed model of P-gp/MDR comprised of two highly conserved units, six putative 
membrane-spanning regions followed by a cytoplasmic nucleotide-binding fold, in 
tandem [39, 40]. From the sequence homology with the bacterial transport systems, it was 
proposed that P-gp/MDR is an energy-dependent transporter that is involved in the efflux 
of drugs to reduce the drug accumulation in MDR cells [39-41]. By this time, it was 
realized that ABC proteins comprised a large protein superfamily [42] conserved from 
bacteria to mammals [43]. 
 
Forty-eight human ABC genes are classified into seven subfamilies (A to G) 
based on the gene structure, amino acid alignment especially of nucleotide binding 
domains (NBD), and phylogenetic analysis and are named according to Human Genome 
Organization (HUGO) guidelines established in 1999 (P-gp/MDR1 is ABCB1 under the 
new nomenclature, http://www.genenames.org/genefamily/abc.php)[44]. ABC gene 
homologs found in other species, e.g., mouse, drosophila, are also classified into similar 
subfamilies. ABC proteins are characterized by the presence of Walker A and B motifs, 
which can be found in other ATP binding proteins, and an additional element, the 
signature motif, in NBD. Except for ABCE and F subfamilies, all ABC proteins also 
contain one or two sets of membrane spanning domains (MSD) consisting of six to 
eleven α-helices. These MSD-containing ABC proteins will be referred to as ABC 
transporters hereafter although some of them, namely ABCC7, ABCC8, and ABCC9, are 
not typical transporters. ABC transporters can further be classified into two types by the 
number of functional units they contain. Functional transporters consist of two sets of 
MSDs and NBDs (Fig. 1.1.); full transporters contain two MSDs and NBDs in a single 
polypeptide, whereas half transporters contain only one MSD and NBD, thus are required 
to either homo- or heterodimerize in order to exert their functions. Full transporters are 
found in ABCA, ABCB, and ABCC subfamilies and half transporters are grouped into 
ABCB, ABCD and ABCG subfamilies.  
 
 
1.2. ABC Transporters 
 
Although ABC transporters were initially identified from MDR cells and were 
implicated in MDR phenotypes, subsequent studies have shown that ABC transporters 
have more fundamental roles: moving molecules, whether xenotoxins or biological 
molecules, across the cell membranes in an energy-dependent and unidirectional manner. 
While most of the prokaryotic ABC proteins pump in compounds, mainly nutrients, from 
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Figure 1.1. Schematic representations of ABC transporters.   
A. Full transporters contain two sets of MSDs and NBDs in tandem. In addition, long 
MRPs contain an extra MSD, MSD0. Domain structure of NBD is shown on the upper 
panel. B. Half transporters contain one set of MSD and NBD. ABCG proteins have a 
reversed orientation of MSD and NBD. Some ABCB half transporters contain an 
additional 3 – 5 TM helices. MSD, Membrane spanning domain; NBD, nucleotide 
binding domain; TM, transmembrane helices. 
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Figure 1.1. (continued). 
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the extracellular milieu into the cells, eukaryotic ABC transporters typically move 
molecules from the cytoplasm to the extracellular compartment or into cellular 
organelles. Functions of some ABC transporters were identified through linkage analysis 
with known human disorders, tissue distribution patterns, and/or animal models.  
 
 
1.2.1. ABC Transporters and MDR Phenotypes 
 
 Multidrug resistance frequently develops in patients undergoing chemotherapy 
and is one of the major reasons for the relapses observed. Mechanisms of MDR have 
been extensively studied for numerous agents and can be classified into either one or a 
combination of the following three patterns: i) decrease in the levels of uptake carriers for 
drugs that do not cross the membranes by passive diffusion, ii) mutations in the target 
molecules or target pathways so that the drugs are no longer effective, and iii) increase in 
levels of the transporters that efflux mainly hydrophobic drugs. Because many ABC 
transporters are able to efflux structurally different classes of drugs, changes in their 
expression levels can explain MDR phenotypes in many cases.  Indeed, when MDR 
phenotypes developed in “spontaneous” mammary tumors from Brca1-/-/p53-/- conditional 
mice in response to doxorubicin, Mdr1a and Mdr1b (mouse P-gp/MDR1) were 
consistantly upregulated in many of the tumors investigated [45]. The tumors also 
became cross-resistant to docetaxel, an excellent P-gp/MDR1 substrate, and became 
sensitive to doxorubicin when treated with a P-gp inhibitor suggesting that the 
upregulation of Mdr1 genes were responsible for the MDR phenotype [45]. 
 
 Prior to 1991, P-gp was believed to be the only drug efflux transporter. However, 
“atypical” MDR phenotypes paved the way for identification of new ABC transporters 
that ply a role in MDR. For example, by taking an advantage of a doxorubicin-selected 
small cell lung cancer cell line, H69AR, with no P-gp overexpression, Cole et al., 
identified an ABC transporter, MRP1 (ABCC1) termed for multidrug resistance-
associated protein 1 [46]. In a concerted approach to identify P-gp independent 
resistance, Ross and colleagues utilized a cell line that was selected for doxorubicin 
resistance, but treated with the P-gp inhibitor, verapamil. From MCF7/AdrVp cell line, 
the third major drug transporter, breast cancer resistance protein (BCRP, also known as 
ABCG2), was identified [47]. When BCRP was stably overexpressed in MCF-7, the cells 
became resistant to doxorubicin, daunomycin, and mitoxantrone, meeting criteria as a 
multidrug transporter [47]. BCRP is also known as ABCP for its high placental 
expression [48] and as MXR for mitoxantrone resistance [49]. Currently, P-gp, MRP1, 
and BCRP are considered to be the three major “drug transporters” for their wide array of 
substrates and their roles in MDR phenotypes seen in many cell lines/tumors. Their 
substrates are not limited to chemotherapeutic agents as they can transport many other 
drugs including antiviral agents, antibiotics, and antimalarials (a concise list of their 
substrates is reviewed in ref. [50]).  
 
 Through the search of human expressed sequence tag (EST) database, the number 
of ABC proteins grew rapidly [44, 51]. Because of the role of P-gp and MRP1 as 
mutidrug transporters, other MDRs (ABCB full transporters) and MRPs have been 
8 
extensively studied to identify clinically relevant substrates. Some were found to be 
overexpressed in drug resistant cells (such as MRP4)[51, 52] and others were found to 
confer drug resistance when ectopically overexrpressed in cells (for a list of drug-
resistant cell and transfection studies, see ref. [53]). There is a significant overlap in the 
substrates among transporters from different subfamilies [50, 54], but there are substrates 
that are characteristics of a certain subfamily. For example, many MRPs transport 
nucleoside and cyclic nucleoside analogs. ABC transporters can also transport drug 
metabolites such as glutathione or glucuronate conjugates or mono-, di-, or tri-
phosphates.  
 
Although not all drug transporters are upregulated in MDR cells, their ability to 
transport a wide array of compounds underscores the importance of identifying 
transporters for clinically used drugs. Not only do ABC transporters play a role in drug 
resistance, they also have critical roles in drug distribution and drug toxicity. For 
example, transporters may reduce drug efficacy by limiting the drug penetration into 
target tissues or impairing absorption leading to sub-therapeutic drug concentrations. On 
the other hand, reduced transporter function may increase susceptibility to adverse effects 
by increasing drug concentrations leading to prolonged exposure. Some ABC transporters 
have reduced activity secondary to non-synonymous single nucleotide polymorphisms 
(SNP). SNPs have been identified that affect the function of P-gp, MRP1, and BCRP 
(summarized in the ref. [55]). ABC transporters themselves can be drug targets given 
their roles in MDR, and several P-gp inhibitors are on clinical trials [53]. However, their 
physiological roles need to be determined to avoid any adverse effects. 
 
 
1.2.2. Physiological Roles of ABC Transporters 
 
 In general, ABC transporters in the plasma membrane play an important role in 
pumping toxic compounds out of the cell or in maintaining cellular homeostasis, whereas 
transporters located on intracellular organelle membranes are involved in diverse 
biological or metabolic processes. Cell membranes provide a first line of barrier to limit 
the access of toxins into the cells or contain them in particular compartments within the 
cells. They can also act as a barrier to maintain a chemical gradient of compounds that do 
not readily cross the lipid bilayers. ABC transporters expressed on the cell surface add 
another layer of protection by actively pumping out toxins or metabolites. In accordance 
with their protective role, ABC transporters are expressed at such sites as blood-brain 
barrier (BBB), blood-placenta barrier, and luminal side of intestine, where the entry of 
toxins is strictly limited due to deleterious effects they may have. Development of animal 
models lacking ABC transporters has revealed unexpected but sometimes critical roles of 
these transporters in normal physiology. 
 
 Many compounds including drugs ingested orally are absorbed from the intestinal 
brush border membrane. Transporters such as P-gp/ABCB1, BCRP/ABCG2, and 
MRP2/ABCC2 are expressed on the apical membrane of intestine and limit the 
absorption of xenotoxins [28, 35, 56]. Increased oral availability of topotecan was 
observed in BCRP knockout (KO) mice supporting the barrier function of BCRP at the 
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level of absorption [35]. Other transporters, such as obligate heterodimers of ABCG5 and 
ABCG8 that limit sterol absorption [36, 57], are also expressed in the intestine. Even if 
the compounds are absorbed in the intestine, they can still be metabolized by hepatic 
cytochrome P450 enzymes for detoxification and excretion through the bile and urine.  
 
The bile mainly consists of cholesterol, various bile acids generated in 
hepatocytes from cholesterol, phospholipids, and bilirubin. Transporters located on the 
canaliculus membrane directly contribute to the content of bile, since they pump their 
substrates into the bile flow. Sinusoidal (basolateral) membranes of the hepatocytes come 
directly in contact with the bloodstream allowing the cells to take up whatever was 
absorbed at the intestine. They also provide a site for releasing the bile acid overload 
during cholestasis when bile flow is blocked or for releasing essential compounds 
generated in the hepatocytes, such as glutathione (GSH), to be circulated in the blood. As 
the major site for detoxification of endo- and exogenous compounds, liver contains a 
number of ABC transporters in order to move them across the membranes to other 
compartments. To name a few, canalicular transporters include P-gp/ABCB1 [56], 
BSEP/ABCB11 [58], MDR3/ABCB4 [59], MRP2/ABCC2 [28], and BCRP/ABCG2 
[35], and sinusoidal transporters include MRP3/ABCC3 [60], MRP4/ABCC4 [61], and 
MRP6/ABCC6 [62]. Many of the substrates for the canalicular transporters were 
identified by analyzing bile contents from the knockout mouse models. For example, bile 
collected from mdr2-/- mouse (MDR3/ABCB4) was completely devoid of phospholipids 
highlighting the role of MDR3 as a biliary phospholipid transporter [59]. BSEP, as its 
name stands for bile salt export pump, transports hydrophobic bile acids into bile [58], 
which is then absorbed by intestine as part of the enterohepatic circulation. On the other 
hand, MRP2/ABCC2 pumps glucuronide-, glutathione-, or sulfate-conjugated 
compounds, which have become more hydrophilic than the original compound, into bile 
to be removed from the system [28]. ABCG5 and ABCG8 have been implicated in 
flipping the cholesterol from the inner to the outer leaflet of canalicular membranes 
affecting biliary excretion of cholesterol and other sterols in a MDR3-dependent manner 
[63, 64]. Basolateral transporters MRP3 and MRP4 have been shown to transport bile 
acids, especially sulfated-bile acids, which cannot be handled by BSEP, into the blood 
perhaps to alleviate the toxic effects of hepatic bile acid accumulation during cholestasis 
[60, 61, 65]. The ABC transporters affect the fate of endo- and exogenous compounds 
both at the levels of intestinal absorption and the hepatic elimination. Mutations in many 
of these transporters are found to be the causes for human diseases. They are summarized 
in Table 1.1. 
 
 Another compartment protected by numerous transporters is brain. Because of its 
essential role in all animals, an entry of compounds into brain is limited by two barriers: 
BBB and blood-cerebrospinal fluid (CSF) barrier (BCB). The BBB function is 
maintained by the endothelium of brain capillaries; tight junctions between the cells do 
not allow paracellular movement of compounds from blood to the brain, whereas apical 
ABC transporters actively pump compounds into blood to limit their brain penetration. 
Several apical ABC transporters are reported including P-gp/ABCB1 [21], MRP2 [66], 
MRP4 [67], MRP5 [68], and BCRP [69]. Their role in BBB function was first identified 
in mdr1a KO mice when the animals suffered neurotoxic side effects from ivermectin 
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due to a 90-fold accumulation of the drug in the brain compared to the wild type mice 
[21]. Similar observations were made using Mrp2 deficient TR- rats and anti-epileptic 
drug [66], and Mrp4 KO mice and topotecan [67]. Apical localization of the transporters 
was also confirmed using immunohistochemistry. The second barrier in the brain to limit 
the uptake of the toxic compounds, BCB, is maintained by epithelial cells in the choroid 
plexus. The apical surface comes directly in contact with CSF; therefore, the basolateral 
transporters pump compounds into blood to prevent brain penetration. MRP1 and MRP4 
have been shown to localize on the basolateral membranes in choroid plexus and to 
contribute to the low etoposide [70] and topotecan [67] concentrations in CSF. P-gp 
localizes at the apical membrane, thus is not responsible for lowering the drug 
concentration at BCB [71]. Although the ABC transporters protect the brain from 
xenotoxins providing two layers of barrier at BBB and BCB, they pose a major challenge 
to treating disorders in the central nervous system (CNS) including brain tumor. 
Therefore, it is critical to determine whether compounds are substrates for certain 
transporters in order to increase the efficacy without increasing systemic adverse effects. 
P-gp and BCRP inhibitors have been tested on pre-clinical models to increase brain 
distribution of CNS-targeted drugs. 
 
 Protective roles of ABC transporters extend to other compartments including 
materno-fetal interface where placental transporters prevent toxic agents from reaching 
the fetus. Significant accumulation of such drugs as paclitaxel and topotecan was found 
in mdr1a-/-/1b-/- and Bcrp-/- embryos respectively [35, 72]. Recent findings also implicate 
a protective role of ABC transporters in stem cells [73, 74].  BCRP has been shown to be 
a stem cell marker and pumps Hoechst 33342 dye out contributing to the side population 
phenotype, which is used to isolate stem cells [74]. BCRP can also confer a survival 
advantage for stem cells under low oxygen conditions known as hypoxia by removing 
excess porphyrins and heme, which can damage membranes and other molecules [75]. 
 
All of the transporters described above that have the ability to pump out toxic 
compounds are expressed at the plasma membrane. Most of the half transporters 
belonging to B and D subfamilies reside on intracellular membranes and are involved in 
diverse biological processes. Transporters associated with antigen processing (TAP) 1 
and TAP2 (ABCB2 and ABCB3 respectively) localized on the endoplasmic reticulum 
(ER) are important molecules in immune response [76, 77]. After an antigen is degraded 
by proteasomes in the cytoplasm, TAP1/TAP2 heterodimers translocate the antigenic 
peptide across the ER membrane. The peptide is then loaded onto major 
histocompatibility complex (MHC) class I molecule, which can then present the antigen 
to T cells at the cell surface [78]. Mutations in TAPs are linked to immunodeficiency [23, 
24]. TAP-like (TAPL, ABCB9) is expressed in the lysosomal membrane [79] where it is 
also thought to transport peptides [80]. Functions of other ABCB half transporters will be 
described in later sections. Although their substrates are not fully understood, 
peroxisomal transporters, ABCD subfamily members, are implicated in beta-oxidation of 
fatty acids [81].  
 
Among the ABC transporters (ABC proteins with MSDs), cystic fibrosis 
transmembrane conductance regulator (CFTR, ABCC7), sulfonylurea receptor 1 (SUR1, 
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ABCC8), and SUR2 (ABCC9) have unique roles in regulating ion concentrations. CFTR 
was initially identified as a cystic fibrosis (CF) causing gene and was later found to 
function as a low conductance Cl- channel [30, 82]. Three SUR proteins, SUR1, and two 
splice variants of SUR2, SUR2A and SUR2B, are regulators of ATP-sensitive K+ 
channels involved in such processes as regulating insulin secretion and vascular tone 
[83], and have no transport function identified to date. 
 
 
1.2.3. ABC Transporters and Diseases/Phenotypes 
 
 About one third of known human ABC genes are associated with phenotypes 
linked to a genetic defect [2]. Well known genetic disorders associated with ABC genes 
include cystic fibrosis, retinal degeneration, and Dubin-Johnson syndrome (summarized 
in Table 1.1., [2]). Variations in a single nucleotide (creating a non-synonymous change) 
may be enough to produce deleterious effects. For example, a single nucleotide mutation 
in ABCB7, which has been implicated in iron homeostasis and iron-sulfur cluster 
formation, is linked to X-linked sideroblastic anemia and ataxia (XLSA/A) [26]. A well-
characterized CFTR mutant, ∆F508 results from a 3-bp deletion to produce a deletion of 
phenylalanine at position 508 [30]. This mutant cannot properly traffick to the plasma 
membrane and instead is targeted for degradation at the ER [84]. Lack of sufficient 
amount of CFTR, a chloride channel, at the membrane results in abnormal ion balance 
and fluid transport in airway cells, which ultimately leads to CF. Cystic fibrosis is the 
most common fatal genetic disease in Caucasians.   
 
 There are other SNPs or mutations reported in ABC genes that do not have severe 
clinical manifestations but may have effect on the protein function. For example, a 
mutation in P-gp gene will increase the sensitivity to drugs that are P-gp substrates. In a 
subset of dogs of the collie breed, a severely truncated P-gp is produced as a result of a 4-
bp deletion in exon 4. In these dogs, insufficient activity of P-gp at BBB causes 
sensitivity to ivermectin, a commonly used veterinary medicine for heartworm prevention 
[21, 22, 85]. A SNP in ABCC11 gene was found to be associated with earwax type, wet 
or dry [33]. Since ABCC11 is implicated in a cyclic nucleotide transport and has been 
shown to transport some drugs [86], it will be of an interest to see if the dry ear wax 
phenotype correlates with sensitivity to ABCC11 substrates. Phenotypes that can be seen 
immediately give an advantage over genotyping when considering tailor made 
therapeutics. Also, sensitivity to a particular drug may indicate impairment in some ABC 
transporters and, therefore, care should be taken when administering drugs that are 
substrates for such transporters. 
 
 
1.2.4. Architecture of ABC Transporters 
 
 It is generally accepted that two sets of MSDs, each containing six 
transmembrane (TM) helices, and NBDs form a functional transport unit, with one set of 
MSD plus one NBD being considered a core unit (Fig. 1.1.)[87]. Introduction of a 
mutation in a single NBD is sufficient to abrogate transport activity, underscoring the 
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importance of having two functional NBDs [88], even though ATP binding and 
hydrolysis at two NBDs are often not equivalent. When full transporters are separated 
into two core units (N- and C-terminal halves), co-expression of both halves is able to 
reconstitute transport activity, suggesting that functional transport units are not required 
to be in a single polypeptide [89, 90]. In accordance, half transporters, which only contain 
a single core unit, either homodimerize as has been suggested for ABCG2 [91] or 
heterodimerize as seen in ABCG5/ABCG8 [57] and TAP1/TAP2 [92]. For obligate 
heterodimers, co-expression of two genes is essential for proper folding and maturation 
[57, 93]. Higher oligomers are reported for some transporters, although their 
physiological roles remain elusive [91]. Domains that are important for dimer formation 
have been reported [94-96], but it is likely that more than one is responsible for the stable 
dimer formation. Recently reported structure of bacterial ABC multidrug transporter, 
Sav1866, also shows that TM helices from two MSDs intertwine to form two wings, 
which open up to release its substrates [97]. Crosslinking studies showed similar TM 
helices arrangement for P-gp [98]. 
 
MSDs have been implicated in substrate binding, thus share a low homology 
among transporters, whereas NBDs, which are responsible for binding and hydrolyzing 
ATP, are highly conserved [42]. As shown in Fig. 1.1., some MRPs contain an additional 
set of MSD, termed MSD0 with five TM helices, and some ABCB half transporters (i.e., 
TAPs) contain three to five additional TM helices [99]. While these domains may have 
an effect on basal transport activity [100], they have been shown to act as docking sites 
for interacting proteins [101] or regulatory domains for transport [102]. In ABCG 
subfamily, the arrangement of MSD and NBD is opposite from the other ABC 
transporters such that N-terminal NBD is followed by MSD. From biochemical and 
kinetic studies, it has been shown that ABC transporters are capable of binding multiple 
compounds simultaneously as seen in other multidrug binding proteins [103-107]. 
Although the use of UV-crosslinking of photoactivatable ligands and mutagenesis studies 
have also identified residues that are involved in the drug binding [108, 109], the 
structural evidence of substrate(s)-bound ABC transporters is required to fully understand 
the precise drug binding site(s). Based on structural information from bacterial multidrug 
binding protein QacR, the drug binding site is thought to contain a number of aromatic 
residues and a couple of charged amino acid residues to neutralize charged compounds 
[105, 106]. Also, the drug binding site contains several “mini-pockets” that can 
accommodate different classes of drugs. These mini-pockets are continuous so that a 
bulky compound can utilize more than one mini-pocket for binding [105]. Since the 
substrate recognition is so complex, it is not feasible to predict substrate specificity based 
on the secondary structures. 
 
To understand the function of NBDs, extensive mutagenesis studies have been 
performed on the conserved regions. In addition, soluble NBDs, unlike MSDs, are 
crystallized and their structures have been determined with or without nucleotide bound 
to them. NBD contains several characteristic domains including Walker A and B motifs, 
signature motif, switch region, and A, D, and Q loops each playing a critical role in 
nucleotide binding and/or hydrolysis (Fig. 1.2.). Both biochemical and structural studies 
have shown that two functional NBDs are required to form functional ATPases and that 
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Figure 1.2. Interaction between ATP and different motifs from two NBDs.  
Mutagenesis studies as well structural data revealed interactions between an ATP 
molecule and key residues in different motifs. Motifs on opposite sides of ATP represent 
two NBDs. This diagram shows that an ATP molecule is sandwiched between two 
NBDs. This explains the need for two NBDs in functional ABC transporters. Reprinted 
from Molecular Cell, Vol 10(1), Smith, P.C., Karpowich, N., Millen, L., Moody, J.E., 
Rosen, J., Thomas, P.J., and Hunt, J.F., ATP binding to the motor domain from an ABC 
transporter drives formation of a nucleotide sandwich dimer, p. 139-149, Copyright 
(2002), with permission from Elsevier [110]. 
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two molecules of ATP are bound at the dimer interface.  The requirement for NBD dimer 
is readily understood by the observation that the Walker A and B motifs, switch region, A 
and Q loops from one NBD and the signature motif and D loop from the other NBD all 
contribute to make up the active ATPase [110]. The A-loop, an aromatic amino acid 
located ~25 amino acid residues upstream of Walker A motif, stacks the adenine ring 
from ATP, and the phosphates are stabilized by Walker A motif, whereas Walker B 
contains a catalytic glutamate. The histidine residue from the switch region promotes 
ATP hydrolysis by stabilizing the γ-phosphate and later the transition state [110, 111]. Q-
loop binds to catalytic water, where D-loop (for dimerization) binds to Mg2+ as well as 
interacting with the catalytic water. The signature motif binds to γ-phosphate of ATP and 
plays a critical role in disengaging the dimer after ATP hydrolysis. However, an 
asymmetry in the NBD exists for many transporters. For TAP1/2, only one ATPase site 
constitutes of consensus motifs, where the other ATPase site has degenerate motifs 
implying that the consensus site is the primary site for ATP hydrolysis for substrate 
transport [111]. 
 
The Sav1866 structure as well the TAP1 structure revealed a soluble linker 
wrapped around the NBDs [97, 112]. In Sav1866, where the structure of the entire 
molecule was solved, the cytoplasmic loops were shown to interact with NBDs possibly 
transmitting information from NBDs to MSDs and vice versa [97]. Unexpectedly, the 
cytoplasmic loops were found to reach over to the NBD from the other molecule, making 
a twisted turn at the interface (Fig. 1.3.) [97]. 
 
 
1.2.5. Transport Mechanism 
 
It has been shown that substrate translocation by ABC transporters requires ATP 
molecules. However, the precise mechanism of the translocation and the role of ATP 
binding and hydrolysis has been controversial. The initial model proposed by Senior et al. 
[113] included ATP binding to an empty NBD, which stimulates hydrolysis of the other 
ATP when a substrate is bound. This produces a change in affinity and results in the 
release of the substrate to the other side. ADP is released, which then resets the 
transporter to the high affinity state. The key points in this model are that only one ATP 
is hydrolyzed per transport cycle and that the ATP hydrolysis alternates between two 
NBDs. The other feature of this model is that the “power-stroke” which translocates 
substrates comes from ATP hydrolysis. On the contrary, recent structural and 
biochemical data favor the “ATP-switch” model, where ATP binding itself is the power-
stroke [114]. In this model, substrate binding at high affinity site favors ATP binding to 
NBDs, which results in the formation of closed dimer. The change in the NBDs is then 
transmitted to MSDs inducing a conformational change to a low affinity state for 
substrates and the outward opening of the TM helices. The substrate is then released and 
the subsequent ATP hydrolysis followed by ADP and Pi release disengage the NBD 
dimer, resetting the transporter to a high affinity site. Accordingly, Sav1866 structure 
shows that the nucleotide binding stabilizes the outward opening of TM helices [97]. 
Substrate binding has been shown to induce a conformational change in many 
transporters [115] and relatively high KM for ATP in isolated NBDs may imply that the 
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Figure 1.3. Bacterial ABC transporter Sav1866 structure.  
Backbone of the homodimeric Sav1866 is shown in ribbon  or coil representation with 
nucleotides bound at cytoplasmic NBDs. Yellow and turquoise represent each subunit in 
the dimer. A. This view shows membrane-embedded TM helices forming outward wings. 
TM helices from two subunits are intertwined to form the wings. Grey region indicates 
the position of predicted lipid bilayers. B. The protein is rotated 90˚ around the vertical 
axis with resprect to A. TM helices in turquoise subunit are numbered. C. Close up view 
of the NBDs. This view shows the cytoplasmic loops coming from turquoise TM helices 
reach NBDs from subunits as colored in red. TM, transmembrane helices; NBDs, 
nucleotide binding domains; ICL, intracellular loops (between TM helices); N-ter, amino 
terminus; C-ter, carboxy terminus. Reprinted by permission from Macmillan Publishers 
Ltd: Nature (Dawson, R.J. and Locher, K.P., Structure of a bacterial multidrug ABC 
transporter. Nature, 2006. 443(7108): p. 180-185.), copyright (2006) [97].
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changes in MSDs promote ATP binding. 
 
 
1.2.6. Regulation of ABC Transporters 
 
 ABC transporter expression is regulated by transcription, translation, and 
degradation and their function is regulated by proper localization, post-translational 
modification, and/or interaction with other proteins. As xenobiotic pumps, many ABC 
transporters are known to be induced by their substrates and other xenobiotics that can 
activate nuclear receptors such as pregnane X receptor (PXR), constitutive androstane 
receptor (CAR), farnesoid X receptor (FXR), and peroxisome proliferators-activated 
receptor gamma (PPARγ) [116]. A number of bile acids activate FXR, which in turn 
induces BSEP/ABCB11, a bile acid transporter in the liver canaliculis [117, 118]. PXR 
activators induce P-gp and MRP2, whereas CAR activators are known to induce P-gp, 
MRP2, and MRP4 [116]. These nuclear receptors regulate expression of many 
metabolizing enzymes namely cytochrome P450’s, which can generate conjugated 
compounds that are substrates for the transpoters. CAR activation results in the 
coordinated upregulation of both Mrp4 and Sult2a1 [119]. Sult2a1 catalyzes the 
formation of sulfated steroids and bile acids, which can be removed from hepatocytes 
especially during cholestasis [119]. Because many drugs can induce or inhibit 
transporters, the drug-drug interaction may cause unexpected adverse effects. Stress 
stimuli are also known to induce ABC transporters in order to protect the cells. For 
example, BCRP/ABCG2 confers a survival advantage to cells during hypoxia and is 
induced by the binding of hypoxia-inducible factor 1 (HIF-1) to the hypoxia response 
element under hypoxic conditions [75]. Epigenetic changes such as promoter methylation 
and histone modification have also been shown to correlate with mRNA levels of 
transporters [120-123]. 
 
 The usage of alternate promoters and splicing has been implicated in mRNA 
expression levels and tissue distribution of BCRP/ABCG2 [124-126]. In addition, 
alternative splicing has been reported for many of the ABCC subfamily members [127-
130]. Some alternatively spliced isoforms still produce functional proteins; however, 
some isoforms contain premature termination codons and are targeted for nonsense-
mediated mRNA decay [129, 130].   
 
 The expression of the ABC transporters can also be regulated at the translational 
level. A synonymous SNP in the coding region of P-gp has been shown to decrease the 
rate of translation resulting in a slightly different folding of the protein [131]. Incorrect 
folding of the protein also does not leave ER and is targeted for degradation as seen with 
CFTR ∆F508 [84]. The mechanisms and the signals for sorting transporters to proper 
membranes such as apical and basolateral membrane, are also being extensively studied; 
however, much is unknown about signals that target transporters to correct membranes. 
Protein stability also plays a role in determining the levels of functional transporters. 
Post-translational modifications such as N-glycosylation of BSEP/ABCB11 and P-gp 
have been shown to affect protein stability or the proper trafficking [132, 133]. Other 
ABC transporters are modified by glycan attachment. However, the role of N-
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glycosylation on ABC transporters has been somewhat inconclusive. For BCRP, the 
glycosylation has been shown not to affect its localization, expression, or transport 
activity [134]. 
 
 Functional regulation of CFTR/ABCC7 has been extensively studied and the 
phosphorylation by PKA has been shown to activate its channel function. CFTR has also 
been shown to have several interacting partners through the C-terminal PDZ domain. 
Functional and physical coupling to the G protein coupled receptors (GPCR) such as β2 
adrenergic receptors [135] and type 2 lysophosphatidic acid receptor [136] have been 
reported. Since CFTR is activated by cyclic adenosine monophosphate (cAMP), the close 
proximity to a cAMP transporter, MRP4 through PDZ interaction attenuates its channel 
activity [137]. TAP1/2 also function in a macromolecular complex called peptide-loading 
complex, which consists of tapasin, MHC class I, ERp57, β2-microglobulin, and 
calreticulin [138]. Further, interaction with other proteins may influence cell surface 
internalization and recycling as seen in GPCRs. 
 
 
1.3. Half Transporters in ABCB Subfamily 
 
 The ABCB subfamily is unique among the other subfamilies because it contains 
both full and half transporters. There are six half transporters in this subfamily, ABCB2, 
B3, and B6-B10. ABCB2 and B3 (TAPs) reside in the ER and ABCB9 (TAPL) in the 
lysosomes, and they are all involved in the translocation of peptides into the respective 
organelles. ABCB6-B8 and B10 localize at the mitochondria and are involved in other 
biological processes, although ABCB10 has been speculated to play a role in transporting 
peptides out of the mitochondria. Phylogenetic analysis revealed that within the B 
subfamily, there are three subgroups: the one containing full transporters, the second one 
containing ABCB2, B3, B8, B9 and B10, and the third one containing B6 and B7 [138]. 
It is not surprising that four transporters involved in peptide transport are clustered in one 
group even though their cellular localizations vary. 
 
 TAP1/2 are one of the well-characterized transporters beside the three major drug 
transporters. The TAP1 NBD has been crystallized and numerous mutagenesis studies 
showed mechanisms and kinetics of peptide transport cycle [111, 112, 139-144]. 
Moreover, the unique topology of TAPs with additional N-terminal TM helices was 
shown to be important for their interaction with tapasin, which is essential for forming 
the peptide-loading complex [99, 101]. TAPs translocate antigenic peptides into ER 
lumen to load them onto MHC class I molecules. Peptide-loaded MHC class I molecules 
are then dissociated from TAPs and present the antigen to T cells at the cell surface 
[138].  
 
 ABCB9 was initially identified from rat as a transporter homologous to TAP1 and 
TAP2 and was thus named TAP-like (TAPL) [145]. Mouse and human ABCB9 was later 
cloned and found to localize in lysosomes by immunofluorescence microscopy and 
gradient centrifugation [79]. Lysosomal localization of ABCB9 was confirmed by 
another group, which also showed ATP-dependent peptide transport into lysosomes by 
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functional ABCB9 [146]. Unlike TAP1/2, ABCB9 is not involved in the antigen 
presentation by MHC class I and has been shown to homodimerize [80, 147]. Although 
the implication of its lysosomal localization is unclear, because ABCB9 expression is 
induced when monocytes differentiate into dendritic cells, professional antigen presenting 
cells, its role in delivering nuclear or cellular peptides to MHC class II has been 
suggested [146]. 
 
 ABCB8 was the first mammalian mitochondrial ABC transporter to be 
characterized [148], but three other mammalian mitochondrial ABC transporters, 
ABCB6, B7, and B10, have been reported to date. Immunofluorescence studies showed a 
co-localization of ABCB8 with MitoTracker, a mitochondria marker. Also, a faster 
mobility in SDS-polyacrylamide gel electrophoresis (SDS-PAGE) when expressed in 
intact cells compared to in vitro translated samples suggested a cleavage of a signal 
peptide. Indeed, the N-terminal of ABCB8 was sufficient for mitochondrial targeting of 
green fluorescent protein (GFP). Although the authors were not able to purify inner and 
mitochondrial outer membranes, the presence of a cleavable signal peptide led to a 
speculation that ABCB8 is in the mitochondrial inner membrane [148]. The substrates for 
ABCB8 are yet to be identified; however, it has been implicated in the cellular protection 
against oxidative stress [149]. Reduction of ABCB8 protein by small interfering RNA 
(siRNA) in neonatal rat cardiomyocytes leads to a loss of mitochondrial membrane 
potential. On the other hand, overexpression of ABCB8 protects cells from hydrogen 
peroxide-induced mitochondria dysfunction [149]. ABCB8 has been found in a large 
cross-linked complex containing four mitochondrial proteins although the physiological 
implication of the complex is unclear [150]. Regardless of what the substrates may be, 
ABCB8 is likely to be involved in the maintenance of mitochondrial membrane potential. 
 
 
1.3.1. ABCB7/Atm1p 
 
 Saccharomyces cerevisiae Atm1p is the first mitochondrial ABC transporter to be 
identified and stands for ABC transporter of mitochondria [151]. Atm1p contains a 
functional mitochondrial targeting sequence at its N-terminus and is localized at the inner 
membrane. The NBD of Atm1p has been suggested to reside in the matrix and, therefore, 
this transporter is considered to move its substrates into the intermembrane space. It 
forms a homodimer and a mutation in the conserved lysine residue in the Walker A 
domain disrupts dimer formation [94]. Yeast cells lacking atm1 display slow growth with 
the increased oxidative stress considered to result from the mitochondrial free iron 
accumulation [152, 153]. Increased sensitivity to the oxidative stress can be attributed 
partly to the reduced catalase activity. Although a decrease in the heme containing 
molecules is seen in the ∆atm1 cells, including catalase and cytochomes, Atm1p is not 
considered a heme transporter [151, 152, 154]. In yeast cells where heme biosynthesis is 
defective, addition of heme rescues the slow growth phenotype, whereas heme does not 
affect the cells lacking atm1, suggesting that reduced levels of heme is a secondary effect 
in ∆atm1 cells [151]. On contrary, Atm1p has been shown to be involved in the 
generation of cytosolic [Fe-S] proteins [155]. Whether Atm1p directly transports the [Fe-
S] cluster or not has not been shown. However, purified Atm1p reportedly shows ATPase 
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activity stimulated by molecules containing sulfhydryl groups, especially by peptides 
containing cysteine residues [156]. If Atm1p substrates include peptides containing 
sulfhydryl groups, then it is not surprising that another mitochondrial peptide transporter 
mdl1 was identified as a high copy suppressor of atm1 to partially rescue the sensitivity 
to oxidative stress [157]. Mdl1p may be able to transport some of Atm1p substrate 
peptides in the absence of Atm1p. Regardless, it is clear that Atm1p plays a role in the 
iron homeostasis in S. cerevisiae. Recent findings in zebrafish show that [Fe-S] clusters 
are required for heme biosynthesis suggesting there is an intricate relationship between 
the two iron-containing molecules [158]. 
 
 Mammalian ABCB7 was identified as the functional ortholog of yeast Atm1p 
[159], and mutations in this gene result in a partial loss of the function causing XLSA/A 
[26, 160, 161]. ABCB7 essentially has the same characteristics as the yeast Atm1p; it 
localizes to the mitochondria, contains a mitochondrial targeting sequence at the N-
terminus, and restores growth, catalase activity, and normal iron level in ∆atm1 strain 
when overexpressed [159]. Abcb7 null mice were embryonic lethal indicating that this 
gene is essential for development [162]. This explains the fact that only partial loss of 
protein function is observed in XLSA/A patients because fetuses harboring the mutations 
resulting in a complete loss of function will not be viable. This underscores the 
importance of [Fe-S] clusters as cofactors to many enzymes including respiratory chain, 
citric acid cycle, ribosome assembly, and amino acid synthesis [156]. Many of the tissue-
specific conditional Abcb7 KO mice were not viable with the exception of the liver-
specific KO animals. Using the liver from these animals, the role of Abcb7 in the 
biogenesis of cytosolic [Fe-S] clusters was confirmed [162]. Total liver iron was 
increased in the knockout mice but there was no significant mitochondrial iron 
accumulation. Because cytosolic [Fe-S] clusters were unavailable, the cells responded as 
if they were under iron depletion (e.g., IRP binding to IRE was increased). 
Mitochondrion appears to be the site for regulating iron homeostasis; it is critical for [Fe-
S] cluster formation, four of the eight steps in heme biosynthesis take place in the 
mitochondria, and mitochondrial ferritin is able to store free iron without damaging 
mitochondrial components. Therefore, it is not surprising that heme synthesis is altered in 
Abcb7 KO animals or cells as a consequence to altered iron homeostasis especially in 
mitochondria. Increased ratio of zinc protoporphyrin IX (PPIX) to heme was observed in 
the blood from chimeric inducible-Abcb7 KO animals [161] and increased PPIX was 
observed in the HeLa cells treated with ABCB7 siRNA [163]. These studies suggested 
that heme biosynthesis was not defective in these systems because PPIX is the 
penultimate product before forming heme and ferrochelatase catalyzes the insertion of 
both iron and zinc atoms into PPIX. Moreover, the mitochondrial ferritin-bound iron was 
significantly reduced in HeLa cells treated with ABCB7 siRNA even in the presence of 
mitochondrial iron accumulation, suggesting this pool of accumulated iron is inaccessible 
to ferrochelatase for heme biosynthesis [163]. Iron is an essential molecule to life and, 
therefore, its usage is tightly regulated. 
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1.3.2. ABCB10/ABC-me 
 
 ABCB10/ABC-me, named for its mitochondrial localization and erythroid 
expression, was originally identified as a GATA-1 target gene [164]. GATA-1 is a 
transcription factor essential for erythropoiesis, and it regulates many erythroid selective 
genes. ABCB10 expression in the sites of definitive hematopoiesis, such as fetal liver and 
adult bone marrow, also supported the potential role of ABCB10 in red cell development 
[164]. Dimethylsulfoxide (DMSO), a known inducer for erythroid maturation, increased 
ABCB10 mRNA expression in murine erythroleukemia (Mel) cells. Moreover, the rate of 
hemoglobin synthesis was greatly increased during DMSO-induced differentiation in Mel 
cells stably expressing ABCB10 [164]. However, the overexpression of ABCB10 in the 
absence of DMSO did not result in the spontaneous differentiation of Mel cells or 
increased hemoglobin synthesis; therefore, it is likely that ABCB10 facilitates the 
DMSO-induced cell differentiation and may require other regulatory proteins/pathways 
[164]. ABCB10 contains a mitochondrial targeting signal at its N-terminus and localizes 
to the inner membrane with NBD in the matrix [164-166]. This orientation suggests 
ABCB10 pumps its substrates from matrix into the intermembrane space. ABCB10 has 
been shown to homodimerize and possibly form an oligomer [165]. The involvement of 
ABCB10 in hemoglobin biosynthesis and its mitochondrial localization suggested that 
ABCB10 might play a role in heme biosynthesis. As mentioned earlier, heme 
biosynthesis occurs both in the matrix and the cytoplasm. Therefore, although the 
substrates for ABCB10 are yet to be identified, it was suggested that ABCB10 
transported heme or its precursors into the intermembrane space [164]. Heme, the end 
product in the heme biosynthesis, reduced ABCB10 mRNA suggesting a feedback 
mechanism to regulate heme biosynthesis [164]. However, the precise role of ABCB10 in 
erythropoiesis still needs to be determined. 
 
 From a phylogenetic analysis, yeast Mdl1p has been suggested to be an ABCB10 
homolog [138]. They both localize to mitochondrial inner membranes and form 
homodimers [165, 167]. Mdl1p exports peptides generated by m-AAA protease in the 
matrix into the intermembrane space [167]. Because ABCB10 clusters with other 
mammalian peptide transporters ABCB2, B3, and B9, it may have a role in peptide 
transport; however, no direct evidence has been presented. 
 
 
1.3.3. Identification of ABCB6 (PRP/UMAT/MTABC3) 
 
 As is the case with many ABC transporters, ABCB6 has more than one name. 
When a partial sequence of rat ABCB6 was cloned in 1997 as a gene upregulated during 
hepatocarcinogenesis, it was named P-gp-related protein (PRP) [168]. Full-length rat 
ABCB6 was cloned in 1998 and was identified as a half transporter [169]. Northern blot 
showed a ubiquitous expression of this transporter with testis having the highest 
expression level [169]. Both studies pointed out a high homology between rABCB6 and 
Schizosaccharomyces pombe heavy metal tolerance-1 (hmt1) protein. Hmt1 localizes to 
the vacuoles in yeast and confers a heavy metal resistance by sequestering toxic metals 
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into vacuoles [170]. Whether ABCB6 has a functional homolog in yeast or not is yet to 
be determined.  
 
In 2000, Mitsuhashi et al. cloned full length human ABCB6 (named MTABC3) 
and showed its mitochondrial localization using immunofluorescence microscopy and 
subcellular fractionation [171]. ABCB6 gene is comprised of 19 exons and is located at 
chromosome 2q36. Ubiquitous expression of ABCB6 in many tissues including skeletal 
muscle, heart, brain, kidney, and pancreas, was confirmed. Because of its mitochondrial 
localization, ABCB6 was introduced into a yeast strain partially defective in Atm1p 
function to determine whether it can complement the function of Atm1p. Exogenous 
ABCB6 expression lowered amounts of free iron in mitochondria to a level comparable 
to Atm1p-expressed cells. However, neither ABCB6 nor Atm1p overexpression restored 
a normal level of mitochondrial iron. Moreover, a non-functional mutant of ABCB6 with 
mutations in the Walker A motif partially rescued ∆atm1 phenotypes in these cells. These 
results suggested that the effect of ABCB6 expression on the iron level was unlikely to be 
transport-function dependent. Therefore, even though ABCB6 was suggested to be a 
homolog of Atm1p in this particular study [171], functional studies and the phylogenetic 
analysis clearly suggest that ABCB7, not ABCB6, is the true ortholog of Atm1p [159]. 
Taken together, ABCB6 appears to be involved in the mitochondrial iron homeostasis 
and possibly cell proliferation but its function remains largely unknown. 
 
 
1.3.4. Transcriptional Regulation of ABCB6 
 
 Genome-wide analyses of transcription factor binding have led to a series of 
discoveries of previously unknown targets. In short, chromatin immunoprecipitation is 
performed using an antibody against a transcription factor of interest. Co-
immunoprecipitated genomic DNA is analyzed by microarray to determine the identity of 
the sequences. ABCB6 promoter has been shown to potentially bind at least three 
transcription factor complexes from such studies. Li et al. showed that Myc/Max complex 
binds to the promoter of ABCB6 in Burkitt’s lymphoma to possibly activate gene 
expression [172]. Similarly, p130 and E2F4 complex was found to bind to the promoter 
of ABCB6 under growth arrest condition to repress the expression [173]. Interestingly, 
they also identified nuclear respiratory factor-1 (NRF1) binding site in the promoter of 
ABCB6 [173]. NRF1 has been shown to regulate the expression of genes involved in 
mitochondrial function and biogenesis [174]. These findings suggest that ABCB6 is 
induced in rapidly proliferating cells and its expression may be coordinated with the 
expression of other mitochondrial proteins.                    
      
 
1.4. Heme Biosynthesis  
 
 Heme is an essential molecule and is, therefore, synthesized in almost all living 
cells with few exceptions. Organisms such as Caenorhabditis elegans, which does not 
have the capability of synthesizing heme, rely on exogenous heme for maintaining 
hemoproteins and iron homeostasis [175]. The tetrapyrrole structure, a backbone 
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structure of heme and porphyrins, is seen in other molecules including chlorophyll and 
vitamin B12. Heme, an iron-containing PPIX, acts as a cofactor for numerous proteins 
involved in a variety of cellular processes. The production of heme is highest in the 
erythroid cells to sustain the robust hemoglobin synthesis, which is required for oxygen 
transport [176]. Another tissue with a high rate of heme biosynthesis is liver, which 
requires heme for the detoxifying enzyme cytochrome P450. In other tissues/cell types, 
heme is involved in many essential biological processes including respiratory chain, 
oxidative metabolism, and signal transduction [176]. Heme also regulates gene 
expression at transcription and translation level and affects protein stability and 
localization [176]. 
 
Even though heme is required for cellular functions, excess heme and porphyrins 
result in unfavorable outcomes [177]. First, iron in the heme can generate free hydroxyl 
radicals via Fenton’s reaction, which damage cellular components such as DNA and 
membranes. Second, protoporphyrins are photosensitizers releasing singlet oxygen 
radicals in a light-dependent manner. Given the cytotoxic effects of iron, heme and 
porphyrins, cells tightly regulate heme biosyntheis by coordinating it with the synthesis 
of apo-hemoproteins. Additionally, removal of excess intracellular heme and porphyrins 
by cell surface transporters alleviates the cytotoxic effects. Heme catabolism by heme 
oxygenases into iron and biliverdin, which is ultimately converted to bilirubin, is another 
mechanism to eliminate excess heme. 
 
 
1.4.1. Heme Biosynthesis and Diseases 
 
 The first step in heme biosynthesis takes place in the mitochondrial matrix, 
followed by four steps in the cytoplasm, and the subsequent three steps in the 
mitochondria complete the process (Fig. 1.4.)[176]. In humans, all eight enzymes 
involved in the heme biosynthesis have been cloned. The heme biosynthesis pathway is 
essentially the same in all human cells; however, because of the robust heme production 
in erythroid cells, erythroid-specific enzymes, either encoded by different genes or 
alternatively spliced, and different regulatory mechanisms exist in these cells. The first 
step in heme biosynthesis, the condensation of glycine and succinyl-CoA, is catalyzed by 
5-aminolevulinate synthase (ALAS). In non-erythroid cells, the formation of ALA is the 
rate-limiting step. However, the translation of erythroid-specific ALAS2 protein is 
regulated by the availability of iron via the iron regulatory proteins/iron responsive 
element (IRP/IRE) pathway, which involves iron-sensing machinery through [Fe-S] 
clusters [179]. Therefore, in erythroid cells, the iron availability for heme is the rate-
limiting step. The end product of the pathway, heme, can also inhibit ALAS2 by binding 
to the enzyme and retaining it in the cytoplasm. ALA formed in the mitochondrial matrix 
is then transported into the cytoplasm by a yet to be identified carrier(s), and is converted 
to a monopyrrole, porphobilinogen (PBG), by ALA dehydratase (ALAD). Subsequent 
enzymatic reactions by PBG-deaminase (PBGD), uroporphyrinogen III synthase 
(UROS), and uroporphyrinogen decarboxylase (UROD) form coproporphyrinogen III 
(CPgenIII). CPIII is then translocated into the intermembrane space of mitochondria, a 
step suggested to involve an energy-dependent carrier [180, 181]. CPgenIII oxidase in the  
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Figure 1.4. Heme biosynthesis pathway. 
First step in heme biosynthesis occurs in mitochondria, followed by four steps in the 
cytosol. Coproporphyrinogen III oxidase and protoporphyrinogen IX oxidase are located 
in the mitochondrial intermembrane space, whereas the last step in heme biosynthesis, an 
insertion of an iron molecule into protoporphyrin IX, takes place in the matrix. Adapted 
by permission. http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT 
_9465.1, accessed September 14, 2008 [178]. 
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intermembrane space then converts CPgenIII to protoporphyrinogen IX. The next 
enzyme in heme biosynthesis is protoporphyrinogen IX oxidase, an integral membrane 
protein in the mitochondrial inner membrane with the active site facing the 
intermembrane space. This enzyme generates the penultimate product, PPIX. The 
insertion of ferrous iron into PPIX is catalyzed by ferrochelatase, which is anchored to 
inner membrane with its active site facing the matrix. How PPIX translocates across the 
inner membrane is not fully understood. Mitochondrial iron used for heme is thought to 
be imported by mitoferrin in the inner membrane, a member of solute carrier family 
(SLC), specifically SLC25 subfamily [182]. At least three pools of iron have been 
suggested to exist in the mitochondria: iron stored in mitochondrial ferritin, [Fe-S] 
clusters, and a pool of iron readily available for ferrochelatase [163]. Further 
investigation is required to understand the precise mechanisms of iron trafficking and 
distribution in the mitochondria as well in the cytoplasm. 
 
Every enzyme in the heme biosynthesis pathway has been shown to cause 
diseases when mutated, underscoring the importance of heme in mammals. Mutations in 
ALAS2 cause XLSA and mutations in the rest of the enzymes lead to various types of 
porphyria [176, 183]. Clinical manifestations include photosensitivity, neuropathy, and 
acute porphyric attack but the severity of porphyrias varies among the subtypes. Also, 
sites of porphyrin overproduction and accumulation characterize two subgroups within 
the seven porphyrias. Defects in UROS and ferrochelatase lead to erythroid porphyrin 
overproduction, whereas defects in the other five enzymes result in hepatic porphyrias 
[183]. Although the porphyrias are inherited disorders, acute porphyria attacks can be 
induced by drugs and other chemicals. 
 
 
1.4.2. Compounds That Interfere with Heme Biosynthesis 
 
  Chemically-induced porphyrias are the results of disturbance in the heme 
biosynthesis pathway. The most commonly used inhibitor for heme biosynthesis in the 
laboratory is succinylacetone (SA), which inhibits ALAD. However, there are several 
clinically relevant compounds that interfere with the heme biosynthesis pathway. 
Barbiturate drugs such as phenobarbital have been known to precipitate porphyria attacks 
in individuals with hereditary hepatic porphyrias by inducing ALAS1, which exaggerates 
porphyrin overproduction [184]. Heavy metals are also known to have effects on heme 
biosyntheis pathway and cause urinary porphyrin excretion in exposed individuals. 
Therefore, heavy metal contamination in the soil is a serious problem in some parts of the 
world. For example, lead toxicity amounts to clinical manifestations of porphyria attacks, 
because it binds to ALAD, and inhibit the enzyme [185]. Lead also inhibits the action of 
ferrochelatase by competing for the binding of iron. The ratio of zinc PPIX to heme 
increases under lead poisoning, which has been implicated in bone marrow toxicity [186]. 
Another heavy metal linked to porphyria is arsenite. Aresenite likely increases urinary 
porphyrin excretion by inhibiting PBGD and UROD [187]. Alcohol has also been linked 
to disruptions in heme biosynthesis, which may be due to an apparent pleiotropic 
inhibition of the following enzymes: ALAD, UROD, CPO, and ferrochelatase [188].  
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1.4.3. Photodynamic Therapy 
 
 The cytotoxic photosensitizing characteristics of porphyrins have proven to be 
quite useful when it comes to detecting and treating some tumors. Malignant tissues 
readily take up and accumulate porphyrins upon administration of ALA. In primary 
malignant glioma, accumulation of porphyrins produced a red fluorescence under specific 
wavelength (375-440 nm) to allow tumor visualization during surgery [189]. Fluorescing 
and non-fluorescing samples from the perimeter of the tumor were histologically 
determined to confirm that the porphyrin fluorescence was an excellent tumor marker. 
The ability of tumor to accumulate porphyrins is the cornerstone of photodynamic 
therapy [190]. Porphyrin-derivatives or ALA, are administered as photosensitizers, and 
activated by light at specific wavelength to induce cell death in tumor lesions. Underlying 
mechanisms of selective porphyrin accumulation and overproduction in tumor cells have 
not been fully understood. It is speculated that the rapidly proliferating tumor cells have a 
higher requirement for energy; thus, rate of heme biosynthesis is increased as with other 
cellular metabolisms. 
 
 
1.5. Heme and Porphyrin Transporters 
 
 The requirement for heme and porphyrin transporters at least in the plasma 
membrane and the mitochondrial membranes is evident. Iron is essential to life and is 
absorbed at the intestinal membranes as inorganic iron or as the more bioavailable heme 
iron from myoglobin and hemoglobin. The uptake of heme at the cell surface has been 
suggested to be carrier-mediated [191]. On the other hand, heme biosynthesis occurs in 
mitochondria and cytoplasm, requiring movement of porphyrin precursors across 
mitochondrial membranes. This transmembrane movement has been suggested to involve 
energy-dependent processes but the identity of protein(s) responsible for such processes 
remains elusive. Moreover, exporters at the cell surface have been shown to play an 
important role in alleviating cytotoxic effects of heme and porphyrins under certain 
conditions. It is also possible that heme transporters on other organelle membranes exist 
in order to compartmentalize heme/porphyrins or to provide heme for apo-homoproteins. 
 
 Porphyrins and heme readily associate with cellular membranes due to their 
hydrophobic heterocyclic moieties, which may contribute to their damaging effects on 
membranes when activated. However, translocation from the outer leaflet of the lipid 
bilayer to the inner leaflet is a much slower process because of their anionic propionate 
side chains [192].  Therefore, the simple diffusion of heme precursor across the 
mitochondrial membranes is not sufficient to sustain the need for robust heme production 
in the erythroid cells. Accordingly, the presence of an energy-dependent transport of 
porphyrins into mitochondria has long been suggested [180, 193]. Similarly, the activity 
of heme uptake at the plasma membrane has also been documented [191]. 
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1.5.1. Heme Importer: Heme Carrier Protein 1 
 
 Heme carrier protein 1 (HCP1) was identified as heme importer from mouse 
duodenum where majority of heme absorption occurs [194]. HCP1 is a member of the 
major facilitator superfamily (MFS, SLC46A1) and localizes to the plasma membrane. 
Overexpression of HCP1 has been shown to increase heme uptake into cells [195]. In 
addition, HCP1 translocates from cytosol to the brush border membrane of enterocytes 
under iron-deprived conditions, suggesting that its function is regulated by cellular 
demand for iron to prevent possible iron overload [194]. Interestingly, Qiu et al. reported 
that HCP1 is a bona fide proton-coupled folate carrier by determining that mutation in 
this gene is the underlying basis for hereditary folate malabsorption [196]. Therefore, the 
physiological role of HCP1 on iron or heme homeostasis warrants further investigation. 
 
 
1.5.2. Heme/Porphyrin Exporters 
 
 As mentioned in the earlier section, Bcrp is a porphyrin exporter at the cell 
surface [75]. Bcrp null mice showed photosensitivity due to an accumulation of 
photosensitizer pheophorbide a (PhA), a chlorophyll-metabolite, which has a tetrapyrrole 
backbone [35]. Not only does BCRP act as an exporter to remove exogenous porphyrins 
but it also acts to remove excess endogenous porphyrins [75]. Compounds with 
tetrapyrrole structures, but not a monopyrrole such as PBG, competed for specific 
binding of BCRP to hemin-agarose. These results suggested that tetrapyrrole backbone 
was important for substrate recognition [75]. Interestingly, BCRP also transports folate, 
illustrating the possible substrate overlap between HCP1 [197]. Due to activation of 
porphyrin biosynthesis, heme precursors are increased under hypoxic conditions, similar 
to levels of BCRP [75]. BCRP function is required to removes excess porphyrins under 
hypoxia protect cells from their cytotoxic effects. 
 
 Another heme exporter was identified through the search for feline leukemia 
virus, subgroup C (FeLV-C) cell surface receptor. FeLV-C receptor (FLVCR) was cloned 
and characterized as a member of MFS located at the cell surface [198]. Cats with FeLV-
C develop severe anemia due to red cell aplasia; therefore, Quigley et al. speculated that 
FLVCR might play a role in red cell differentiation. Accordingly, overexpression of 
FLVCR reduced heme accumulation into cells and the inhibition of FLVCR function by 
FeLV-C interfered with erythroid differentiation [199]. From these results, it was 
suggested that FLVCR acts as an “overflow valve” in erythroid cells to prevent the 
accumulation of free heme when there is not enough globin synthesized. Definitive proof 
was presented, however, when they showed that Flvcr null mice were embryonic lethal 
and lacked definitive erythropoiesis [200]. Flvcr null embryos had pale livers and lacked 
Ter119 positive cells, suggesting an arrest in erythropoiesis. The role of FLVCR as a 
heme exporter in differentiating erythroid cells emphasizes the importance of highly 
regulated heme biosynthesis and its utilization. Even in differentiating erythroid cells, 
where robust heme production is required, heme levels need regulation in order to avoid 
their cytotoxic and potentially deleterious effects on the terminal differentiation. 
However, FLVCR mRNA decreases as the erythroid cell differentiation proceeds [199], 
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supporting the idea that FLVCR is required at the critical point where globin synthesis 
has not caught up with the heme biosynthesis. 
 
In order to study the function of FLVCR, Flvcrflox/flox;Mx-Cre was generated, where 
interferon administration induces a Cre recombinase activity. In this system, Flvcr gene 
can be knocked out in postnatal mice [200]. The mice developed severe hyperchromic 
macrocytic anemia with iron accumulation in such cells as splenic macrophages, 
hepatocytes, and duodenal enterocyes. Cardiomegaly and splenomegaly were also 
observed as consequences of severe anemia. These results indicate that FLVCR is 
involved in systemic iron homeostasis through heme transport. In human, FLVCR is 
highly expressed in tissues with high iron and/or heme traffick: duodenum, liver, spleen, 
uterus, placenta, and cultured macrophages. By using the iron-storage protein, ferritin, as 
a read-out, FLVCR was implicated in heme efflux from macrophages after they engulf 
senescent red blood cells. These results suggest that heme acquired from red blood cells 
may be recycled instead of being broken down by heme oxygenases. Also, Keel et al. 
speculate that the expression of FLVCR in the liver is important for biliary excretion of 
heme, although this claim needs further investigation.  
 
 
1.5.3. Intracellular Porphyrin Transporters 
 
  Much is unknown about intracellular movement of heme and porphyrins. 
However, few proteins have been shown to either bind heme or be involved in the 
transport of heme or porphyrin. In many instances, porphyrin binding and transport are 
indistinguishable, making the interpretations of the data somewhat difficult. 
 
 Peripheral-type benzodiazepine receptor (PBR), originally identified as 
benzodiazepine receptor on the mitochondrial outer membrane, has been suggested to act 
as a porphyrin transporter. PPIX and CPIII were shown to compete for the binding of 
radiolabeled benzodiazepine to PBR [201]. Moreover, PBR expression was induced 
during the erythroid differentiation [202]. Taken together, Taketani et al. proposed a role 
for PBR in erythroid differentiation, acting as a porphyrin transporter in the heme 
biosynthesis pathway. There is no evidence to support this claim since direct porphyrin 
transport has not been shown to date. It is still possible that PBR is a porphyrin-binding 
component of a protein complex that trasnlocates porphyrins across the membrane.  
 
 Members of SLC25 subfamily are mitochondrial carrier proteins involved in the 
movement of many solutes and metabolites that are critical for mitochondrial functions. 
SLC25A11, also known as 2-oxoglutarate carrier (OGC), is a mitochondrial inner 
membrane protein, which transports 2-oxoglutarate into mitochondria in exchange for 
malate. Imported 2-oxoglutarate is then used for various metabolic pathways in the 
mitochondria including citrate cycle. Using metalloporphyrin-conjugated beads, OGC 
was identified as a porphyrin binding protein [203]. Hemin, PPIX, and CPIII all 
competed for 2-oxoglutarate uptake into mitochondria suggesting a competitive binding 
on OGC [203]. In addition, mitochondrial porphyrin uptake was inhibited by 2-
oxoglutarate [203]. These findings led to a conclusion that OGC is a porphyrin 
28 
transporter involved in the movement of porphyrins from the intermembrane space to 
matrix. However, OGC inhibitor was only able to inhibit the porphyrin accumulation by 
50% and the highest inhibition observed was about 40% at the highest dose of 2-
oxoglutarate used (50 mM) [203]. The relevance of porphyrin transport by OGC in the 
heme biosynthesis pathway still needs to be determined. 
29 
CHAPTER 2.  CHARACTERIZATION OF ABCB6 AS A PORPHYRIN 
TRANSPORTER* 
 
 
2.1. Introduction 
 
Heme, an iron-containing porphyrin, is an essential molecule and has a crucial 
role in oxygen transport as a cofactor for globins [176]. However, heme plays important 
roles in many other biological processes such as metabolism and detoxification of 
biological compounds and xenotoxins (cytochromes, catalase, and peroxidase), oxidative 
phosphorylation (complex II-IV), signal transduction (adenylate and guanylate cyclases), 
and transcription regulation (N-PAS2 and Bach1) [176].  Heme also regulates a number 
of genes by affecting transcription, translation, protein targeting, and protein stability 
[205-209]. Even though heme and pophyrins are fundamental to life, excess heme and 
porphyrins have cytotoxic effects; iron in heme produces hydroxyl radicals via Fenton’s 
reaction and porphyrins absorb light and generate oxygen radicals [177]. Therefore, 
intracellular levels of heme and porphyrin are tightly regulated. Deleterious effects of 
dysregulated heme biosyntheis are readily seen in the forms of various porphyrias or 
sideroblastic anemia [176, 183]. 
 
Heme biosynthesis takes place in two subcellular compartments: the mitochondria 
and the cytoplasm [176]. The first step in heme biosynthesis is the formation of ALA 
from glycine and succinyl-CoA in the mitochondrial matrix. The next step occurs in the 
cytoplasm where ALA is converted to a monopyrrole, PBG, followed by three enzymatic 
reactions to yield CPgenIII. The last three steps in heme biosynthesis take place in the 
mitochondria with an iron insertion into PPIX being the last step. The tetrapyrrole ring 
backbone, which can be found in heme and its precursors, chlorophyll and its 
metabolites, and vitamin B12, in CPgenIII is lipophilic and readily associates with the 
membrane. However, the anionic propionate side chains in CPgenIII make it a challenge 
to cross lipid bilayers with a simple diffusion [192]. In accordance, the uptake of the 
CPgenIII has been suggested to involve an energy-dependent active transport [193]. Even 
though several proteins have been identified to transport porphyrins across the plasma 
membrane (BCRP, FLVCR, and HCP1), the intracellular porphyrin transport process 
remains elusive [210]. However, the high rate of heme biosynthesis, especially in 
erythroid cells, requires such transporter(s) at the mitochondrial membrane to actively 
move heme precursor, CPgenIII, into the intermembrane space in order to facilitate the 
heme biosynthesis.  
 
 The ABC transporters translocate a wide array of compounds across the plasma 
membrane and the subcellular membranes in an ATP-dependent manner. Because of their 
ability to transport numerous compounds, ABC transporters play a role in many 
                                                
* Modified with permission. Krishnamurthy, P.C., Du, G., Fukuda, Y., Sun, D., Sampath, 
J., Mercer, K.E., Wang, J., Sosa-Pineda, B., Murti, K.G., and Schuetz, J.D., Identification 
of a mammalian mitochondrial porphyrin transporter. Nature, 2006. 443(7111): p. 586-
589.  
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biological processes including antigen presentation, insulin secretion, and cellular 
differentiation [2]. Physiological roles of many ABC transporters have been identified by 
the usage of KO animal models or by tissue distribution pattern. Variations in ABC 
transporters are the underlying molecular basis for a number of human disorders and 
phenotypes, which have also led to the identification of their function. The core unit of 
ABC transporters is composed of one MSD and one NBD aligned in tandem. Functional 
transporters require two of such units; MSDs composed of six TM helices bind 
substrates, whereas the NBDs bind and hydrolyze ATP molecules, thus, energizing the 
transport cycle. Full transporters contain two core units in a single polypeptide, whereas 
half transporters only contain one unit and are required to homo- or hetero-dimerize in 
order to exert their function. Half transporter ABCB6 localizes to the mitochondria [171], 
where three other members of the ABCB subfamily reside. ABCB6 is induced during 
liver regeneration and is associated with the mitochondrial iron homeostasis [168, 171]. 
The mitochondria play an important role in cellular iron homeostasis because they are the 
sites for heme biosynthesis, [Fe-S] cluster formation, and iron storage in mitochondrial 
ferritin [156].  
 
In order to understand the physiological role of ABCB6, other authors in this 
study examined the tissue distribution pattern of ABCB6. They demonstrated that 
ABCB6 mRNA is highly expressed in human fetal liver and mouse embryonic liver by 
Northern blot and in situ hybridization, respectively. In addition, database search revealed 
that ABCB6 is highly expressed in both human bone marrow and CD71+ early erythroid 
cells. These expression patterns suggested that ABCB6 is highly expressed in the site of 
erythropoiesis or in the cells with robust heme production. Increased cellular porphyrin 
levels by an addition of ALA or hemin, which is reduced to heme intracellularly, induced 
ABCB6 both at mRNA and protein levels. Taken together, we hypothesized that ABCB6 
plays a role in intracellular trafficking of porphyrins. ABCB6 was also induced in the 
animal models with altered heme/porphyrin levels; increased splenic erythropoiesis by 
phenylhydrazine treatment or increased cellular PPIX levels due to a lack of Bcrp gene 
both induced Abcb6 mRNA. These results further indicated that ABCB6 responds to an 
enhanced heme biosynthesis or increased cellular porphyrins. In order to gain insights 
into the role of ABCB6 in heme biosynthesis, the precise localization of ABCB6 in 
mitochondria was determined by separating mitochondrial inner and outer membranes on 
sucrose gradient. ABCB6 exclusively co-localized with the mitochondrial outer 
membrane markers. Further, proteinase K digestion on the intact mitochondria expressing 
C-terminally tagged ABCB6 showed that the C-terminus of ABCB6 localizes in the 
cytoplasm. These results indicated that ABCB6, localized to the mitochondrial outer 
membrane, transports its substrates into the intermembrane space from the cytoplasm. 
Given its location, direction of transport, and induction by elevated intracellular 
porphyrins, we hypothesized that ABCB6 may be the elusive porphyrin transporter that 
shuttles the heme precursor into the mitochondria. In accordance with this hypothesis, 
binding of ABCB6 to the agarose-conjugated hemin was confirmed.  
 
My contribution to this study was to determine the substrates for ABCB6 and to 
show that the elevated levels of PPIX in ABCB6 overexpressing cells require functional 
ABCB6. By confirming that ABCB6 forms a homodimer, we were able to characterize 
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ABCB6 function using cells overxpressing ABCB6 alone. The affinity for different heme 
precursors as well as other tetrapyrroles was tested to determine the structural 
requirement for ABCB6 binding. To definitively show that the transport function of 
ABCB6 was responsible for the observed effect of ABCB6 on heme biosynthesis, I 
generated human erythroleukemia cell line, K562, stably expressing either wild-type 
ABCB6 or non-functional Walker A ABCB6 mutant (in later chapter, this mutant is 
shown to be defective in ATP binding). Using these cell lines, other authors of this study 
showed that the ATP-dependent mitochondrial hemin uptake was seen only when the 
wild-type ABCB6 was expressed. I also showed that the substrate-stimulated ATPase and 
the elevated basal PPIX levels required a functional ABCB6. Other authors then showed 
that de novo heme biosynthesis was also upregulated in cells that expressed functional 
ABCB6. These findings indicate that ABCB6 is a porphyrin transporter that shuttles 
heme precursors into the mitochondria from the cytoplasm, thereby facilitating heme 
biosynthesis. 
 
 
2.2. Experimental Procedures 
 
 
2.2.1. Cell Culture and Transfection 
 
NIH3T3 and K562 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 4500 mg/L glucose supplemented with 10% FCS, 2 mM L-
glutamine, and penicillin and streptomycin (Gibco) in the presence of 5% CO2 and 
humidified atmosphere. Cells were transfected using LipofectAMINE Plus (Invitrogen) 
according to the manufacturer’s protocols. Cells were plated on 6 well-clustered dish at 3 
x 105 cells/well 24 hours prior to transfection. For each transfection, 1 µg of indicated 
plasmid was used unless otherwise noted.  
 
 To obtain K562 cells stably expressing ABCB6-V5 or ABCB6-K629G-V5, 
pcDNA3.1-hABCB6-V5 or pcDNA3.1-hABCB6-K629G-V5 was introduced into K562 
cells by electroporation. Cells were selected with G418 for two weeks before the 
expression of ABCB6 was tested by immunoblotting. 
 
 
2.2.2. Site-Directed Mutagenesis  
 
Plasmids pcDNA3-hABCB6-FLAG and pcDNA3.1-hABCB6-V5-His were 
designed to express human ABCB6 with C-terminal tags, FLAG or V5 respectively. A 
point mutation was introduced into pcDNA3.1-hABCB6-V5-His using a Quikchange 
site-directed mutagenesis kit (Stratagene, La Jolla, CA) and primers (K629G; sense, 5’- 
GTGGGCCCATCTGGGGCAGGGGGGAGCACAATTTTGCGCCTGCTG-3’, 
antisense, 5’-CAGCAGGCGCAAAATTGTGCTCCCCCCTGCCCCAGATGGGCCCA-
C-3’, G508L; sense 5’- CAGAACCTGGTGATTGGGCTCCTGCTCCTCGCCGGCTC-
CCTGCTTTG-3’, antisense, 5’- CAAAGCAGGGAGCCGGCGAGGAGCAGGAGCC-
CAATCACCAGGTTCTG-3’, G512L; sense 5’- GATTGGGCTCGGGCTCCTCGCCC-
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TCTCCCTGCTTTGCGCATACTTTG-3’, antisense, 5’- CAAAGTATGCGCAAAGC-
AGGGAGAGGGCGAGGAGCCCGAGCCCAATC-3’, G508,512L; sense, 5’- GAACC-
TGGTGATTGGGCTCCTGCTCCTCGCCCTCTCCCTGCTTTGCGCATAC-3’, 
antisense, 5’- GTATGCGCAAAGCAGGGAGAGGGCGAGGAGCAGGAGCCCAAT-
CACCAGGTTC-3’, D641A; sense, 5’- GCCTGCTGTTTCGCTTCTACGCCATCAGC-
TCTGGCTGCATCCG-3’, antisense, 5’- CGGATGCAGCCAGAGCTGATGGCGTAG-
AAGCGAAACAGCAGGC-3’, D650A; sense, 5’- GCTCTGGCTGCATCCGAATAGC-
TGGGCAGGACATTTCACAGGTGAC-3’, antisense, 5’- GTCACCTGTGAAATGTC-
CTGCCCAGCTATTCGGATGCAGCCAGAGC-3’). All genes were thoroughly 
sequenced after mutagenesis. 
 
 
2.2.3. Immunoblotting and Immunoprecipitation 
 
Twenty-four hours after transfection, cells were washed with phosphate buffered 
saline (PBS) and harvested into 1 ml ice-cold PBS containing 1x protease inhibitor 
cocktail (Complete EDTA free, Roche). Cell suspensions were centrifuged at 1,500 x 
rpm for 4 min at 4˚C. Cells were resuspended in Buffer A (50 mM Tris-HCl (pH 7.4), 
150 mM NaCl, 10% glycerol, and 1 x protease inhibitor cocktail (Roche)), and then 
sonicated. After the final concentration of 1% NP-40 was added, the cells were 
solubilized for 60 min at 4˚C with a constant rocking, followed by centrifugation at 3,000 
x rpm for 5 min at 4˚C to remove cell debris. The supernatant was further subjected to 
immnoblotting or immunoprecipitaiton after protein concentration was measured by 
Bradford method (Protein Assay, Bio-Rad Laboratories, Inc.). Final concentration of 1 x 
Laemmli sample buffer (Bio-Rad) was added to the supernatant for immunoblotting. For 
immunoprecipitation, the lysate was incubated with an anti-V5 monoclonal antibody 
(Invitrogen) or an anti-FLAG antibody monoclonal antibody (M2, Sigma) at 1:150 
dilution, and Protein A Sepharose beads (Amersham Pharmacia Biotech., Liscataway, 
NJ) for 2 hr. The samples were washed twice with wash buffer (Buffer A containing 1% 
NP-40), and then Laemmli sample buffer was added to the immnoprecipitates. For 
immnoblotting, proteins were separated on 10% SDS-PAGE and transferred onto 
nitrocellulose membrane (Schleicher & Schuell Biosciences, Inc., Keene, NH). The 
membrane was blocked with 10% skim milk in PBS-T (PBS and 0.1% Tween 20) and 
then incubated with an anti-V5 polyclonal antibody (MBL, Japan) or anti-FLAG 
polyclonal antibody (Sigma). The blot was washed with PBS-T, and then incubated with 
horseradish peroxidase-conjugated anti-rabbit IgG F(ab’)2 fragment (Amersham 
Pharmacia Biotech.). The blot was washed again with PBS-T and detection was 
performed with enhanced chemiluminescence detection (ECL, Amersham Pharmacia 
Biotech.). 
 
 
2.2.4. Crude Mitochondria Preparation 
 
K562 cells were pelleted, washed with PBS, and resuspended in resuspension 
buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl (pH 7.6), and 1 x protease 
inhibitor cocktail (Roche). After 10 min incubation on ice to allow the cells to swell, they 
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were broken with type B Dounce homogenizer. 2.5 x membrane stabilizing buffer (525 
mM mannitol, 175 mM sucrose, 12.5 mM Tris-HCl (pH 7.6), and 2.5 mM EDTA) was 
added to the homogenate to a final concentration of 1 x. The samples were centrifuged at 
1,300 x g for 5 min at 4 ˚C to remove cell debris and nuclei. The supernatant was further 
centrifuged at 17,000 x g for 15 min at 4˚C to pellet mitochondria. 
 
 
2.2.5. Hemin-Agarose Pull-Down Assay 
 
Cell lysates prepared from NIH3T3 cells transiently expressing ABCB6-V5 or 
ABCB6-K629G-V5 as described above were incubated with hemin-agarose for 30 min at 
24˚C. For competition assays, indicated compounds were preincubated with the lysates 
for 5 min prior to an addition of hemin-agarose. The resin was washed for three times 
with wash buffer, and the proteins were eluted using 1 x Laemmli sample buffer 
containing β-ME. ABCB6 bound to hemin-agarose was analyzed by immunoblotting. 
 
 
2.2.6. ATPase Activity Measurement 
 
The vanadate-sensitive ATPase activity in the crude mitochondria isolated from 
K562, K562-ABCB6-Flag, K562-ABCB6-V5, and K562-ABCB6-K629G-V5 (Walker A 
mutant) was measured by the colorimetric assay as described previously [211]. The 
isolated mitochondria preparations containing 30 µg of protein were incubated with 
indicated concentrations of CPIII (prepared in methanol) or PBG (prepared in ddH2O), 
and the reaction was started with the addition of 3.3 mM MgATP. The vanadate-sensitive 
CPIII- and PBG-stimulated ATPase activities were detected and calculated as the release 
of inorganic phosphate (nmol Pi released/min/mg protein). Then the ATPase activity was 
expressed as a fold change relative to the basal vanadate-sensitive ATPase activity. The 
values are average of two to four measurements ± S.E.M. 
 
 
2.2.7. Cellular PPIX Measurements 
 
 Cellular PPIX levels were measured by flow cytometry. Cells were harvested by 
centrifugation, washed and resuspended in PBS. The PPIX fluorescence was measured 
using a Vantage flow cytometer (BD Biosciences) in which the excitation wavelength 
was set at 405 nm and the emission filter was set at 695/40 nm. 
 
 
2.3. Results 
 
 
2.3.1. ABCB6 Homodimerizes 
 
 Half transporters need to either homo- or hetero-dimerize in order to exert their 
functions; however, whether ABCB6 homodimerized had not been determined. We 
34 
postulated that ABCB6 functions as a homodimer because of two findings: i) 
overexpression of ABCB6 alone in cells elevated PPIX levels and ii) three other known 
mitochondrial ABC transporters localize in the inner mitochondrial membrane and, 
therefore, are unlikely to dimerize with the mitochondrial outer membrane ABCB6. To 
test if ABCB6 homodimerized, co-immunoprecipitation using differently tagged ABCB6 
was performed. ABCB6-Flag and ABCB6-V5 were transiently co-expressed in NIH3T3 
cells and lysates prepared. Anti-V5 or anti-Flag antibody was used to immunoprecipitate 
V5- or Flag-tagged ABCB6, respectively, and Flag- or V5-tagged ABCB6 in the 
immunocomplex was analyzed by immunoblotting (Fig. 2.1.). Both V5- and Flag-tagged 
ABCB6 were found in the immunoprecipitates when anti-Flag antibody was used to 
immunoprecipitate ABCB6-Flag indicating that ABCB6-V5 and ABCB6-Flag interact. 
Similar results were obtained when anti-V5 antibody was used to immunoprecipitate 
ABCB6-V5.  These results indicate that ABCB6 homodimerizes and suggest that it does 
not require a heterodimeric partner. 
 
To determine the function of ABCB6, we then developed mutant ABCB6 and 
focused on a domain that has been reported to affect either dimerization and/or function. 
Substitution of the conserved lysine residue in the Walker A motif in the NBD impairs 
transport activity of many ABC transporters [212, 213]. Further, previous studies have 
shown several consequences of the substitution of this residue in half-transporters 
including the loss of stable homodimer formation of Atm1p [94], the decreased targeting 
of BCRP to the plasma membrane [214], and the loss of ATP binding by TAP1 [212]. 
We generated a mutant ABCB6 construct in which the conserved lysine residue is 
substituted with a glycine residue. Differently tagged wild-type and Walker A mutant 
ABCB6-K629G were transiently transfected in NIH3T3 cells in the indicated 
combinations (Fig. 2.2.). Co-immunoprecipitation using anti-Flag antibody showed that 
the Walker A mutant both homodimerizes and heterodimerizes with wild-type ABCB6.  
 
ABCB6 contains two other motifs that have been shown to affect the packing of 
α-helices of membrane proteins or homodimerization of yeast protein. Therefore, we next 
tested the contribution of these two motifs in ABCB6 dimerization. In several membrane 
proteins, the GXXXG motif is suggested to be important in the packing of α-helices in 
transmembrane regions [215-217]. Based upon studies showing a conserved GXXXG 
was important for BCRP transport activity [95], we also evaluated the contribution of this 
motif to ABCB6 homodimerization. There are four GXXXG motifs present in ABCB6; 
therefore, in order to select GXXXG motif that may reside in the membrane-spanning 
domain, transmembrane α-helix regions in ABCB6 were predicted using three programs, 
SOSUI, TopPred, and TMHMM [218-220]. All three programs predicted only the 
GXXXG at amino acid residues 508 through 512 to be in an α-helix. Thus, point 
mutations were introduced to substitute Gly508 and Gly512 with leucine residues. Yeast 
protein Gts1p homodimerizes through a region (DXXXGXXXXD) that is very similar to 
a downstream region of the Walker A motif of several ABC transporters [221]. Also, the 
binding of C-terminal regions of yeast ABC transporter Mdl1p to Gts1p was lost or 
diminished when the aspartate residues were substituted with alanine residues [221]. 
ABCB6 contains a highly similar sequence at the downstream of the Walker A motif. 
Thus, Asp641 and Asp650 were substituted with alanine residues to evaluate the role of 
35 
 
 
Figure 2.1. Homodimerization of ABCB6.  
NIH 3T3 cells were transiently transfected with plasmids encoding ABCB6-FLAG and 
ABCB6-V5. Twenty four hours after transfection, cell lysates were prepared and were 
incubated with anti-FLAG (M2) or anti-V5 antibodies and with Protein A Sepharose 
beads. The immunoprecipitates were washed twice with wash buffer, and the samples 
were analyzed by immunoblotting. TL: total lysate. 
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Figure 2.2. Mutation in the Walker A motif does not affect ABCB6 dimerization.  
NIH 3T3 cells were transiently transfected with plasmids encoding ABCB6-FLAG, 
ABCB6-V5, or indicated K629G mutants. The immunoprecipitation was performed as 
described in the Fig. 2.1. 
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this motif in ABCB6 dimerization. NIH3T3 cells were transiently co-transfected with 
ABCB6-Flag and mutant constructs as indicated. Anti-Flag antibody was used to 
immunoprecipitate ABCB6-Flag from lysates and the interaction between mutant 
ABCB6 proteins and wild type ABCB6 was analyzed by immunoblotting using anti-V5 
antibody (Fig. 2.3.). As shown in Fig. 2.3, all the mutants co-immunoprecipitated with 
wild type ABCB6 indicating that neither of the motifs are critical for ABCB6 
dimerization. Moreover, the substrate binding was retained in G508/512L mutant as 
shown by the hemin-agarose pull-down assay (Fig. 2.4.). Therefore, GXXXG motif is 
unlikely to affect the packing of TM helices, unlike BCRP where transport activity was 
abolished [95]. 
 
 
2.3.2. Interaction between ABCB6 and Heme Is Disrupted by Tetrapyrroles 
 
 ABC transporters translocate structurally different classes of compounds; 
however, the substrate specificity cannot be predicted from the amino acid sequence at 
present due to little structural information and thus, needs to be tested directly by 
determining binding affinity or by measuring transport activity. Other authors of this 
study showed that ABCB6 binds to hemin conjugated to agarose beads. The binding was 
specific because a naturally occurring splice variant of ABCB6, which lacks 50 amino 
acids but still localizes to mitochondria, did not bind to hemin-agarose. Therefore, I next 
tested whether other compounds with a tetrapyrrole ring would displace ABCB6 from 
hemin-agarose (Fig. 2.5.). Cell lysates were prepared from NIH3T3 cells transiently 
expressing ABCB6-V5 and were incubated with indicated compounds before hemin-
agarose pull-down assays. Notably, CPIII, an oxidized form of heme precursor CPgenIII 
that needs to be shuttled into the mitochondria from the cytoplasm, was most potent in 
displacing ABCB6 from hemin-agarose. Commercially available CPIII was used instead 
of physiologically relevant CPgenIII because CPgenIII is readily oxidized to CPIII in 
normal conditions. Another heme precursor, PPIX, also competed for binding to ABCB6 
at a higher concentration. On the other hand, PBG, a monopyrrole heme precursor, had 
no effect on ABCB6 binding to hemin-agarose even at the highest concentration tested 
(80 µM). PhA, a chlorophyll metabolite with a tetrapyrrole backbone, was effective in 
displacing ABCB6 from hemin-agarose at 10 µM, whereas vitamin B12, a tetrapyrrole 
ring with a bulky side chain, was not, even at the highest concentration. These results 
show that ABCB6 preferentially binds compounds with a tetrapyrrole structure with 
anionic propionate side chains.   
 
 
2.3.3. ABCB6 Transports Porphyrins in an ATP-Dependent Manner 
 
Transport cycles by ABC transporters are fueled by ATP hydrolysis. The 
transport process by ABC transporters begins with the binding of their substrates at 
MSDs and ends with the stimulation of ATPase activity at NBDs resetting the transporter 
for the next cycle. Because various porphyrins bind to ABCB6, we next tested whether 
they can stimulate ATPase activity of ABCB6 and if they are transported into isolated 
mitochondria in an ATP-dependent manner. Since a mutation of the conserved lysine  
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Figure 2.3. GXXXG and the D(X)8D domains are not critical for the dimerization.  
NIH 3T3 cells were transiently transfected with plasmids encoding ABCB6-FLAG, 
ABCB6-V5, or indicated mutants, and immunoprecipitation was performed as described 
in Fig. 2.1. All the mutants interacted with ABCB6. TL, total lysate. 
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Figure 2.4. Walker A mutant and GXXXG mutant bind hemin-agarose.
Hemin-agarose pull-down assay was performed using lysates prepared from NIH3T3 
cells transiently transfected with indicated plasmids. TL, total lysate. 
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Figure 2.5. CPIII, PPIX, and PhA displace ABCB6 from hemin-agarose.  
Cell lysates from NIH3T3 cells transiently transfected with ABCB6-V5 were pre-
incubated with indicated amounts of compounds prior to hemin-agarose pull-down 
assays. ABCB6 bound to hemin-agarose was analyzed by immunoblotting using anti-V5 
antibody. The incubation with CPIII, hemin, PP IX, and PhA (tetrapyrroles) decreased 
the amount of ABCB6 in hemin-agarose pull-down fraction, whereas, vitamin B12 and a 
monopyrrole, porphobilinogen had no effect. CPIII; coproporphyrin III, PP IX; 
protoporphyrin IX, PBG; porphobilinogen, PhA; pheophorbide a, Vit B12; vitamin B12. 
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residue in the Walker A motif impairs the transport activity of many ABC transporters, 
we decided to use the Walker A mutant, ABCB6-K629G-V5 as a control in these 
experiments. I generated K562 cell lines that stably expressed either ABCB6-V5 or 
ABCB6-K629G-V5 using G418 selection and selected for clones that expressed 
comparable amounts of proteins. Crude mitochondrial preparations from these cell lines 
were tested for ABCB6 and the mutant protein and the results indicate the mutant protein, 
as well as the wild-type ABCB6, is enriched in this mitochondrial fraction (Fig. 2.6.). 
Vanadate-sensitive ATPase activity was measured in these mitochondrial preparations as 
a release of inorganic phosphates using a colorimetric assay. CPIII-stimulated ATPase 
activity was observed with mitochondria expressing ABCB6 but not with those 
expressing the Walker A mutant protein (Fig. 2.6.). Further, other authors of this study 
showed that the uptake of 55Fe-labeled hemin by mitochondria expressing ABCB6 was 
ATP- and temperature-dependent suggesting that the transport requires ATP hydrolysis. 
The transport activity was abolished in the mitochondria expressing the Walker A 
mutant, which retained the heme-binding ability (Fig. 2.4.), further supporting that 
ABCB6 transports porphyrins into mitochoncria in an ATP dependent manner. A 
tetrapyrrole, CPIII, but not a monopyrrole, PBG, competed for hemin uptake into 
mitochondria. Taken together, CPIII showed a strong competition for binding of hemin-
agarose to ABCB6, stimulated ATPase activity, and inhibited hemin uptake into 
mitochondria.  
 
 
2.3.4. ABCB6 Increases the Rate of Porphyrin Biosynthesis 
 
 ABCB6 is induced by both erythroid differentiation and increased intracellular 
porphyrin levels. Because ABCB6 levels appear to be coordinated with heme 
biosynthesis, we next tested the role of ABCB6 in heme biosynthesis. Using K562 stable 
cell lines, I was able to show an elevated basal PPIX levels in cells expressing the wild-
type ABCB6 compared to K562 parental cells or cells expressing the Walker A mutant 
(Fig. 2.7.). To determine whether the higher PPIX accumulation was due to an increased 
rate of de novo heme biosynthesis in ABCB6 expressing cells, other authors of this study 
determined the amount of radiolabeled glycine incorporated into porphyrins. In both 
mouse and human erythroid cell lines, Mel and K562, respectively, cells expressing 
ABCB6 exhibited higher rate of de novo porphyrin biosynthesis. In CHO-TRex system 
where gene expression can be induced by the addition of tetracycline, ABCB6 expressing 
cells had a higher rate of de novo heme biosynthesis compared to the Walker A mutant 
expressing cells. A loss of one Abcb6 allele in 129/SVJ-derived embryonic stem (ES) cell 
lines resulted in a lower PPIX levels compared to Abcb6+/+ cells when treated with ALA, 
suggesting a lower porphyrin biosynthesis in cells lacking one Abcb6 allele.  
 
 
2.4. Discussion 
 
 Previously, mitochondrial half transporter ABCB6 was implicated in cellular iron 
homeostasis and was suggested to be the functional homolog of yeast Atm1p [171]. 
However, phylogenetic analyses and the functional studies showed that ABCB7 is the  
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Figure 2.6. CPIII stimulates ATPase activity in ABCB6 expressing mitochondria.  
A) Both wild type and the Walker A mutant are enriched in the crude mitochondria 
fraction. Crude mitochondria preparations were isolated from K562 cells stably 
expressing either ABCB6-V5 or the Walker A mutant using differential centrifugation 
and analyzed by immunoblotting using anti-V5 antibody. B) Vanadate sensitive ATPase 
activity was measured as inorganic phosphate release. Crude mitochondria preparations 
from K562 cells stably expressing ABCB6 or the Walker mutant was incubated with 
varying amounts of CPIII. The values are expressed as measurements ± S.E.M. 
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Figure 2.7. ABCB6 expressing cells exhibit higher intracellular PPIX levels. 
The intracellular PPIX levels in the K562 cells expressing vector, ABCB6 or the Walker 
A mutant (ABCB6 MT) were measured by FACS analysis. 
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functional orthlog of Atm1p [159]. Therefore, the physiological role and the substrates of 
ABCB6 remained elusive. The high expression levels of ABCB6 in fetal liver and 
erythroid-lineage cells, its mitochondrial localization, and coordinated gene expression 
with heme biosynthesis and erythroid differentiation led us to identify the role of 
ABCB6in heme biosynthesis. In this study, I showed that ABCB6 is a homodimer that 
binds to various porphyrins and that its ATPase activity is stimulated by a porphyrin, 
CPIII. Furthermore, generation of a cell line stably expressing the Walker A mutant 
ABCB6 enabled us to distinguish porphyrin binding from the transport activity involving 
ATP binding and hydrolysis. The elevated basal levels of PPIX were seen in cells 
expressing wild type ABCB6 but not in the cells expressing the Walker A mutant 
showing that the transport function of ABCB6 is required for the observed effect. Our 
results suggest that ABCB6 is ideally located on the mitochondrial outer membrane to 
transport a heme precursor, CPgenIII, into the intermembrane space to overcome a 
possible rate-limiting step, thereby facilitating heme biosynthesis. 
 
The affinity for porphyrins, mitochondrial uptake of hemin, and CPIII-stimulated 
ATPase activity in ABCB6-expressing cells all demonstrate that porphyrins are ABCB6 
substrates. The affinity of ABCB6 for heme-related porphryins was highest for CPIII, 
followed by hemin, and then by PPIX. Especially, an oxidized form of a heme 
intermediate CPgenIII, CPIII, displaced more than 90% of ABCB6 from hemin-agarose 
at 10 µM.  The monopyrrole PBG did not disrupt the interaction between ABCB6 and 
hemin-agarose. Notably, a plant tetrapyrrole and a mitochondrial toxin, pheophorbide a 
also displaced ABCB6 from hemin-agarose effectively. Generally, the ATPase activity of 
ABC transporters is induced by a substrate binding. Therefore, the observation that 
ATPase activity is induced in the CPIII-treated ABCB6 expressing mitochondria further 
supports CPIII, and possibly other porphyrins as ABCB6 substrates. Further, the uptake 
of hemin into ABCB6 expressing mitochondria conclusively shows that the porphyrins 
are ABCB6 substrates. The temperature and ATP dependence of the hemin uptake 
suggests that ATP hydrolysis fuels the transport cycle. Accordingly, the Walker A 
mutant, which lacks ATPase activity, failed to transport hemin. Moreover, by using the 
Walker A mutant, which still interacted with hemin-agarose, we excluded the possibility 
that the increased 55Fe-hemin in the ABCB6 expressing mitochondria was simply due to 
the binding of hemin to ABCB6 at the mitochondrial membrane. These results indicate 
that heme and other porphyrins are substrates of ABCB6. 
 
The basal PPIX levels are increased in ABCB6-expressing cells compared to the 
vector cells, and accordingly the accelerated rate of de novo porphyrin biosynthesis was 
confirmed. In contrast, cells expressing the Walker A mutant ABCB6 behaved much like 
vector cells and no increase in the PPIX levels nor the de novo porphyrin synthesis was 
observed. These results indicate that the effect of ABCB6 on heme biosynthesis is 
dependent on its transport function. In this study, we showed that ABCB6 interacts with 
porphyrins and localizes on the mitochondrial outer membrane. Furthermore, the C-
terminal tail of ABCB6 resides in the cytoplasm, which strongly suggests that ABCB6 
transports its substrates from the cytoplasm into the intermembrane space. Hemin uptake 
by ABCB6-expressing mitochondria also indicates the same direction of transport. From 
these results, we postulated that ABCB6 is an ideal candidate for shuttling the heme 
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precursor, CPgenIII, into the mitochondria, thus facilitating the heme biosyntheis. The 
proposed role of ABCB6 as a CPgenIII transporter explains the accelerated rate of heme 
biosynthesis because moving the CPgenIII into the intermembrane space, where the next 
enzyme in the pathway resides, may overcome the possible rate-limiting step. Moreover, 
our finding that PPIX levels are lower in the Abcb6+/- ES cells after ALA treatment is 
consistent with the role of ABCB6 in heme biosynthesis.Taken together, these results 
strongly suggest CPgenIII as one of the physiological substrates for ABCB6. 
 
ABCB6 homodimerizes, and therefore, is unlikely to require a heterodimeric 
partner. This finding was important because some ABC half transporters form obligate 
heterodimers and the co-expression of heterodimeric partner is required for the proper 
localization and the function [57]. The overexpression of a single protein ABCB6 was 
sufficient to increase the PPIX levels and enhance mitochondrial hemin uptake, which is 
consistent with ABCB6 functioning as a homodimer. Several domains are reported to be 
important for the dimerization of ABC half transporters or other membrane proteins. The 
yeast ABC transporter Atm1p failed to form a stable homodimer when the conserved 
lysine residue in the Walker A motif was mutated [94]. Another motif implicated in the 
packing of α-helices, GXXXG, is studied in several membrane proteins including ABC 
transporters [95, 215, 216]. Mutation of the GXXXG in BCRP did not impair dimer 
formation, although its transport function was altered [95]. A domain that is similar to a 
downstream region of the Walker A motif of several ABC transporters is a critical 
domain for the homodimerization of the yeast protein Gts1p [221]. Moreover, the 
mutation of the aspartate residues in the domain (DXXXGXXXXD) resulted in a loss or 
a diminished interaction between C-terminal regions of yeast ABC transporter Mdl1p and 
Gts1p [221]. Generation of mutant ABCB6 that is impaired in the dimer formation would 
be useful to test whether the dimerization is required for substrate binding, localization, 
and the function. All of the mutants tested (Walker A, GXXXG, and DXXXGXXXXD) 
interacted with the wild type ABCB6 protein indicating that none of these domains are 
critical for the homodimerization of ABCB6. However, it is possible that the multiple 
domains are involved in the formation of a stable dimer and that a loss of one domain 
does not immediately result in a lack of dimer formation. Furthermore, because the 
conserved lysine residue in the Walker A motif and the DXXXGXXXXD motif are 
located in the NBD, mutations in these domains may affect the formation of NBD dimer 
rather than the overall dimerization, which may result in an altered ATP binding and 
hydrolysis. 
 
In this study, we demonstrate that the mitochondrial ABC transporter ABCB6 is a 
porphyrin transporter on the mitochondrial outer membrane. Because ABCB6 positively 
regulates heme biosynthesis, we speculate that ABCB6 transports CPgenIII into the 
mitochondrial intermembrane space where it is then converted into PPgenIX. The 
transmembrane movement of the anionic porphyrin CPgenIII has been suggested to 
involve an ATP-dependent active transport. Therefore, ABCB6, ideally located on the 
mitochondrial outer membrane, may be the elusive porphyrin transporter required to 
overcome the possible rate-limiting step in heme biosynthesis. The coordinated 
upregulation of ABCB6 during erythroid differentiation and elevated porphyrin 
biosynthesis is consistent with its role in heme biosynthesis. ABCB6 may transport heme 
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into the mitochondria in order to supply heme for mitochondrial hemoproteins, whereas 
compartmentalization of porphyrins may protect plasma membrane and other cellular 
components from their cytotoxic effects.  Like other ABC transporters, we anticipate 
ABCB6 to transport a wide array of substrates; however, the current finding on its 
porphyrin transport and its role in heme biosynthesis delineates its unique physiological 
role. 
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CHAPTER 3.  ABCB6 PROVIDES INSIGHTS INTO THE MECHANISM FOR 
SUBSTRATE TRANSPORT BY ABC TRANSPORTERS 
 
 
3.1. Introduction 
 
 ABC transporters constitute a large protein superfamily, which is involved in the 
transport of a wide array of substrates including xenobiotics and biological metabolites 
across lipid bilayers [2]. The transport of various drugs is the basis for the multidrug 
resistance phenotype conferred by an overexpression of certain ABC transporters, 
whereas many others are implicated in the homeostasis of biomolecules, thus being 
identified as disease causing genes in many human disorders. For transport activity, ABC 
transporters require two MSDs and two NBDs. Half transporters, which consist of one 
NBD and one MSD, therefore, need to either homo- or hetero-dimerize in order to 
reconstitute transport activity. MSDs, generally composed of six TM helices, function in 
substrate binding and determine the substrate specificity. The transport of substrates by 
ABC transporters is energy-dependent and is linked to ATP binding and/or ATP 
hydrolysis at NBDs.   
 
In order to understand how the transport cycle is driven by NBDs, extensive 
biochemical and structural studies have been performed using mutants and nucleotide 
analogs to trap ABC transporters in different states during the transport cycle. Crystal 
structures of isolated NBDs demonstrated that ATP-bound NBDs form a stable dimer, 
where two ATP molecules are sandwiched by the two NBDs, providing the basis for the 
requirement of two NBDs [110]. The NBDs are highly conserved among ABC 
transporters and contain motifs such as Walker A and B, ABC signature, H and Q loops 
[111]. The structures of isolated NBDs showed that ATP is bound by Walker A and B 
motifs from one NBD and by ABC signature motif from the other [110]. Substitution of 
the conserved lysine residue in the Walker A motif impaired ATP binding in some and 
ATP hydrolysis in other ABC transporters [111, 212, 213, 222, 223]. On the other hand, 
substitution of the conserved glutamate residue in the Walker B motif abolished ATPase 
activity and subsequent release of ADP and Pi to confirm its role in ATP hydrolysis, thus 
making this mutation useful when studying the structure of nucleotide-bound NBD [213]. 
The position of ATP between two NBDs explains the requirement for having two 
functional NBDs to complete the transport cycle including ATP hydrolysis. Previous 
studies suggest that the two NBDs are required for ATP binding and hydrolysis but are 
not equivalent in some transporters, i.e., one NBD has a higher affinity for ATP and other 
has a higher ATPase activity. This seems to be the case for some full transporters such as 
ABCC1 [222], as well as half transporters that form heterodimers including 
TAP1/ABCB2 and TAP2ABCB3 [111]. However, for Mdl1, a homodimeric 
mitochondrial half transporter, such asymmetry does not appear to exist and the ATP 
binding and hydrolysis occur in a stepwise manner [224].  
 
A number of studies have established a coordinated action between MSDs and 
NBDs in the substrate translocation by ABC transporters. Although there may be some 
variations among different ABC transporters, the transport cycle is initiated upon binding 
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of a substrate(s) to the MSDs, followed by ATP binding or ADP to ATP exchange at the 
NBDs. It has been proposed that the subsequent ATP hydrolysis provides the energy to 
translocate the substrate to the other side of the lipid bilayers [113, 115]. However, recent 
biochemical and structural studies have implicated another mechanism for ATP-driven 
substrate transport [97, 114]. Sometimes referred to as “ATP switch model,” the model 
postulates that MSDs alternate between high-affinity state and low-affinity state for a 
substrate and that the ATP binding and ATP hydrolysis trigger the conformational 
changes to allow for releasing the substrate and resetting the transporter, respectively 
[114]. A substrate binds to the MSDs at a high-affinity substrate site. ATP binding to the 
NBDs induces a formation of a closed NBD dimer, which is coupled to conformational 
changes in the MSDs resulting in a switch to a low-affinity substrate binding state, thus 
translocating the substrate. Subsequent ATP hydrolysis disengages the NBD dimer, 
thereby resetting the ABC transporter to a high-affinity state to start a new transport 
cycle. Indeed, studies show that ATP binding to transporters such as Pgp induces a 
conformational change as shown by different patterns of tryptic digestion [225]. In 
addition, radiolabeled ligand binding assays have shown that MRP1 adapts a low-affinity 
substrate site in the presence of nucleotides [226]. However, much of the structural 
studies regarding nucleotide-bound NBDs have used isolated NBDs so how the changes 
in NBDs transmit the information to MSDs is speculative [110, 111]. Variations appear 
to exist within the two proposed transport models among the transporters. Nevertheless, 
understanding transport mechanism is important to develop approaches to block 
transporter functions. Since some half transporters confer resistance to drug therapy, 
namely ABCG2/BCRP, it is important to understand the transport mechanism in half 
transporters that form homodimers, which would have homologous NBDs. ABCB6 is 
another half-transporter, shown to be a homodimer, and is localized to the mitochondrial 
outer membrane. ABCB6 transports heme precursors/porphyrins into mitochondria, 
thereby facilitating heme biosynthesis [204]. Since ABCB6 binds to heme conjugated to 
agarose beads, it is an ideal model to study substrate binding and also the transport 
mechanism. 
 
In this study, we used ABCB6 and its Walker A lysine mutant to determine the 
effect of nucleotide binding on substrate affinity. The conserved lysine residue in the 
Walker A motif is critical for ATP binding and /or hydrolysis of ABC transporters and is 
also shown to be important for the homodimerization of yeast mitochondrial ABC 
transporter, Atm1p. We have shown that the Walker A mutant lacks ATP-dependent 
heme transport activity and that the lysine mutation does not affect the homodimerization 
of ABCB6. In this study, we show that the substrate binding, assessed by using hemin 
conjugated to agarose beads, is affected in the Walker A mutant only modestly. However, 
the affinity for ATP was drastically reduced. We determined the effect of ATP and 
AMPPNP binding to ABCB6-hemin-agarose complex and provided insights into the role 
of nucleotide binding in conformational changes in MSDs.  
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3.2. Experimental Procedures 
 
 
3.2.1. Cell Culture and Transfection 
 
NIH3T3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 4500 mg/L glucose supplemented with 10% FCS, 2 mM L-glutamine, and 
antibiotics (Gibco). Cells were plated on 6 well-clustered dish at 3 x 105 cells/well 24 
hours prior to transfection and were transfected using LipofectAMINE Plus (Invitrogen) 
according to the manufacturer’s protocols. 
 
 
3.2.2. Site-Directed Mutagenesis 
 
pcDNA3.1-hABCB6-V5-His plasmid was designed to express human ABCB6 
with a C-terminal Flag tag. A point mutation was introduced to substitute the lysine 
residue at 629 in Walker A motif with a glycine residue using a Quikchange site-directed 
mutagenesis kit (Stratagene) and primers (K629G sense; 5’- GTGGGCCCATCTGGGG-
CAGGGGGGAGCACAATTTTGCGCCTGCTG-3’, K629G antisense; 5’- CAGCAGG-
CGCAAAATTGTGCTCCCCCCTGCCCCAGATGGGCCCAC-3’). All genes were 
thoroughly sequenced after mutagenesis.  
 
 
3.2.3. Immunoblotting 
 
NIH3T3 cells were transiently transfected with expression plasmids indicated in 
the legends. Twenty-four hours after transfection, cells were washed with phosphate 
buffered-saline (PBS), scraped into ice-cold PBS containing protease inhibitor cocktail 
(complete EDTA free, Roche), and resuspended in buffer A (50 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 10% glycerol, and 1 x protease inhibitor cocktail). The samples were then 
sonicated and the final concentration of 1% Nonidet P40 added and solubilized by 
constant rocking for 1 hr. The samples were centrifuged at 16,000 x g for 15 min at 4˚C 
to remove cell debris. The protein concentration was quantified by Bradford method 
(Protein assay, Bio-Rad) and lysate was further subjected to immunoblotting or pull-
down assays. For immunoblotting, samples were subjected to 10% Laemmli SDS-PAGE  
and transferred to a nitrocellulose membrane (Amersham Pharmacia). The blot was 
blocked for 2 hr with blocking buffer (10% skim milk in PBS containing 0.1% Tween 20, 
PBS-T), incubated with anti-V5 polyclonal (MBL, Japan) antibody for 2 hr, and washed 
four times with PBS-T.  Subsequently, the blot was incubated with anti-rabbit or mouse 
IgG conjugated to horse radish peroxidase (Amersham Pharmacia) for 1 hr, followed by 
washing with PBS-T for four times. The bands were detected using enhanced 
chemiluminescence detection kits (ECL, Amersham Pharmacia). 
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3.2.4. Hemin-Agarose or ATP-Agarose Pull-Down Assays 
 
Cell lysates prepared from cells transfected with ABCB6-V5 or ABCB6-K629G-
V5 expression plasmids were incubated with hemin conjugated to agarose beads (Sigma) 
or ATP-agarose (N6, Sigma) for 30 min or indicated times at 24˚C. The samples were 
washed with wash buffer and analyzed by immunoblotting using anti-V5 polyclonal 
antibody. The intensity of the bands was analyzed by densitometry using Image J 
(http://rsb.info.nih.gov/ij). 
 
 
3.2.5. Nucleotide-Induced ABCB6 Dissociation 
 
Cell lysates were incubated with hemin-agarose for 30 min at 24˚C to form 
ABCB6-hemin-agarose complex. The resin was washed once and resuspended in 200 µl 
buffer A. The indicated amounts of ATP or AMPPNP were added to the samples. After 
30 min incubation at 24˚C, the amounts of ABCB6 protein remained bound to the resin 
were analyzed by immunoblotting and densitometry. 
 
 
3.3. Results 
 
 
3.3.1. ABCB6 and ABCB6K629G Display Similar Kinetics for Hemin Binding 
 
Transport activity/mechanism of ABC transporters has been studied rigorously 
using mutant forms of proteins in which critical residues involved in the ATP binding 
and/or ATP hydrolysis have been substituted with other amino acids, which result in a 
loss of function [213, 222]. We have previously generated an ABCB6 mutant construct in 
which the conserved lysine residue in the Walker A motif is substituted with a glycine 
residue (ABCB6K629G) (Fig. 2.2.). In accordance with previous reports on the other ABC 
transporters, ABCB6K629G mutant protein lacks heme transport activity and cells 
expressing ABCB6K629G do not accumulate PPIX, an indicator of functional ABCB6 
[204]. Moreover, the mutant ABCB6 homodimerizes. To determine the substrate binding 
to ABCB6K629G mutant, hemin-agarose pull-down assays were perfomed. Lysates from 
NIH3T3 cells transiently transfected with ABCB6-V5 or ABCB6K629G -V5 were 
incubated with hemin conjugated to agarose beads, and proteins bound to the hemin-
agarose were analyzed by immunoblotting (Fig. 2.5.). ABCB6K629G -V5 mutant 
effectively interacted with hemin-agarose at equilibrium, suggesting that the 
conformation of substrate (hemin) binding site is not altered grossly by a mutation in the 
NBD. Binding of ABCB6 to hemin-agarose is specific as pre-incubation of lysates with 
hemin (80 µM) can compete for the binding and a deletion mutant of ABCB6 does not 
bind to hemin-agarose [204]. 
 
To further characterize the binding of hemin-agarose to ABCB6 and ABCB6K629G 
at equilibrium, different amounts of hemin-agarose were incubated with lysates for the 
pull-down assays, and intensity of the bands from immunoblots was quantified by 
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densitometry and plotted as a function of hemin-agarose concentration. The binding of 
ABCB6 or ABCB6K629G to hemin-agarose was dependent on the amount of hemin-
agarose added as shown in Fig. 3.1.A.  
 
 Binding of hemin to ABCB6K629G-V5 was further characterized by determining 
the association kinetics. Hemin-agarose pull-down assays were performed at different 
time points, and intensity of the bands from Western blot was quantified by densitometry 
and plotted as a function of time (Fig. 3.1.B). Non-linear regression equation was used to 
perform the curve fitting. There was no significant difference between ABCB6-V5 and 
ABCB6K629G-V5 on forming a complex with hemin-agarose.  
 
 
3.3.2. Loss of the Walker A Lysine Results in Reduced ATP Binding 
 
  The substitution of conserved lysine residue in the Walker A motif of ABCB6 did 
not affect the dimerization and modestly reduced the rate of ABCB6 association with 
hemin. Therefore, the loss of function observed with ABCB6K629G is due either to 
changes in the levels of ATP binding or ATP hydrolysis, both of which are critical to 
transport activity. To determine the ATP binding of ABCB6 and ABCB6K629G, an ATP-
agarose pull-down assay was performed at 24˚C. ABCB6-V5 bound to ATP-garose in a 
concentration dependent manner, whereas the majority of ABCB6K629G-V5 was 
recovered in the flow through even at the highest concentration of ATP-agarose used 
(Fig. 3.2.A).  
 
  In order to identify whether the loss of affinity for ATP observed with the mutant 
protein was unique to lysine to glycine substitution, the homology modeling of NBD 
from ABCB6 with several substitutions was performed by Jufang Shan using Hlyb, α-
hemolysin translocation ATP-binding protein, bound to ATP as a template (Fig. 3.2.B, 
only the NBDs with K, K to G, and K to M are shown). In both the mutants, the favorable 
interaction between the phosphate group from ATP and the side chain of the lysine is 
lost. When free energy for ATP binding was calculated for each mutants (G, M, A, S, T, 
and Q), all the mutants had a positive ∆∆G value compared to the wild type (K) 
suggesting that the ATP binding is unfavorable for these mutants. However, when 
ABCB6K629G-V5 is incubated with ATP-agarose at 37˚C, small amount of ABCB6K629G-
V5 binds to the beads (Fig. 3.2.C). Therefore, the loss of function seen with 
ABCB6K629G-V5 can be attributed to its significantly reduced affinity for ATP. In 
accordance with the calculated ∆∆G values for ATP binding of the other mutant NBDs, 
substitution of the conserved lysine residue to M, A, S, T, and Q also resulted in a 
reduced affinity for ATP (Fig. 3.2.D). 
 
 
3.3.3. ATP Binding to ABCB6 Changes Its Affinity for Hemin-Agarose 
 
According to the ATP-swith model, release of a substrate from ABC transporters 
requires a conformational change from a high affinity substrate binding state to a low 
affinity state [114]. If ATP binding is sufficient to induce this conformational change in  
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Figure 3.1. ABCB6 and ABCB6K629G binds to hemin-agarose with similar kinetics.  
A) ABCB6 and ABCB6K629G show similar Bmax and kd obs.  Cell lysates prepared from 
NIH 3T3 cells transiently transfected with a plasmid encoding ABCB6-V5 or 
ABCB6K629G were incubated with varying amounts of hemin-agarose beads at 24˚C. 
Hemin-agarose beads were washed twice, and the samples were analyzed by 
immunoblotting. B) The association kinetics is similar for the wild type and mutant 
ABCB6. Cell lysates were incubated with hemin-agarose for indicated times at24˚C. The 
values are measurement ± S.D. 
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Figure 3.2. ATP-binding is severely impaired in Walker A mutant ABCB6.  
A) Cell lysates were prepared from NIH 3T3 cells transiently transfected with a plasmid 
encoding ABCB6-V5 or ABCB6K629G and incubated with varying amounts of ATP-
agarose beads (conjugated at N-6) at 24˚C. ATP-agarose beads were washed twice, and 
the samples were analyzed by immunoblotting. Flow through from the pull-down assays 
was TCA precipitated and also analyzed. B) NBDs from ABCB6, K629G, and K629M 
based on homology modeling show a loss of favorable interaction between the phosphate 
group of ATP and the side chain from lysine residue. C) Low levels of ABCB6K629G bind 
to ATP-agarose at 37˚C. Cell lysates were prepared as described above and incubated 
with ATP-agarose at 37˚C. D) Substitution of lysine residue disrupts ATP binding in 
ABCB6. Various mutants were tested for ATP binding. 
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Figure 3.2. (continued). 
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ABCB6, it should dissociate from hemin-agarose upon binding to ATP. On the other 
hand, if the ATP hydrolysis is required for the conformational change, then the 
incubation with a non-hydrolyzable ATP analog, AMPPNP, will not release ABCB6 
from hemin-agarose. Cell lysate was incubated with hemin-agarose and the resultant 
complex was purified. Various amounts of ATP were added to the ABCB6-hemin-
agarose complex at 24˚C and the amount of ABCB6 that remained bound to hemin-
agarose was determined by immunoblotting (Fig. 3.3.A). Forty-percent of ABCB6 
dissociated from hemin-agarose in the presence of 50 µM ATP, whereas ABCB6K629G, 
which has much lower affinity for ATP, shows no decrease in hemin-agarose binding. At 
lower ATP concentrations, ABCB6K629G shows a slight increase in hemin-binding, which 
is not observed with ABCB6 wild type, for unknown reasons. Nevertheless, ABCB6K629G 
dissociation from hemin-agarose is minimal even at the highest ATP concentration tested 
(0.5 mM, <20%) in contrast to the wild type ABCB6, in which more than 60% of 
ABCB6 dissociated from the beads. 
 
At 24˚C, the rate of ATP hydrolysis is not at its maximum, but to exclude the 
possibility of ATP hydrolysis playing a role in the dissociation of ABCB6 from hemin-
agarose, AMPPNP, a non-hydrolyzable ATP analog, was used (Fig. 3.3.B, C). Upon the 
addition of AMPPNP to ABCB6-hemin-agarose complex, the ABCB6 dissociated from 
hemin-agarose, whereas it had an opposite effect on ABCB6K629G. Compared to ATP, 
higher concentration of AMPPNP was required to induce dissociation of ABCB6 from 
hemin-agarose. However, it is in good agreement with previous studies that showed 4 
mM AMPPNP was required for binding to MRP1 [227]. 
 
 
3.4. Discussion 
 
 The nucleotide binding to ABCB6 prompted release of ABCB6 from hemin-
agarose. The change of a high affinity state to a low affinity state for hemin-agarose does 
not require ATP hydrolysis because a non-hydrolyzable ATP analog, AMPPNP, 
effectively disrupts the interaction between ABCB6 and hemin-agarose. Our results here 
are consistent with a substrate transport model where the formation of NBD dimer upon 
substrate and nucleotide binding provide the power stroke for transport. Moreover, unlike 
another mitochondrial half transporter, Atm1p, a mutation in the conserved lysine in the 
Walker A domain did not affect homodimerization of ABCB6. The mutation, however, 
drastically impaired the ATP binding to ABCB6. Therefore, nucleotides did not have 
effects on the Walker A mutant ABCB6 bound to hemin-agarose. 
 
The mutation of the conserved lysine residue in Walker A motif has different 
effects depending on ABC transporters [213]. This can be partly attributed to the 
asymmetrical NBDs in many full transporters and the heterodimeric half transporters, 
where one site shows a low affinity for ATP or low ATPase activity. In the asymmetrical 
NBDs, one ATPase site contains the consensus sequence whereas the other site contains a 
degenerate sequence [111]. Therefore, the mutation in the degenerate site may not result 
in a lack of transport activity, because the consensus site provides all the functionalities 
(e.g., ATP binding and hydrolysis). Because the Walker A mutant ABCB6 
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Figure 3.3. Binding of nucleotides to ABCB6 changes affinity for hemin-agarose.  
A) A schematic drawing of roles ATP binding and ATP hydrolysis can play in substrate 
transport cycle. B) ATP induces a conformational change from a high affinity substrate 
binding to a low affinity binding state. C) AMPPNP induces a dissociation of ABCB6 
from hemin-agarose. 
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homodimerizes, both ATPase sites contain mutated Walker motif and, therefore, ATP 
binding is severely impaired. Whether ABCB6 is normally bound to ATP or ADP under 
physiological conditions, which was suggested for TAP1/TAP2 heterodimer [111], still 
needs to be determined. In TAP1/TAP2, substrate binding promotes ATP exchange at the 
NBD, which results in the formation of NBD dimer. The substrate binding is unlikely to 
be affected by the presence of ATP because ATP depletion does not affect peptide 
binding to TAP1/TAP2 [228]. In addition, inability to bind ATP did not affect the Walker 
A mutant ABCB6 binding to hemin-agarose. In either case, ATP binding affects the 
dimer formation of NBD [110, 111, 224]. Purified TAP1/TAP2 NBDs do not 
heterodimerize, suggesting that the formation of dimer is not an intrinsic feature [111].  
 
The equilibrium binding to hemin-agarose saturated at 1 mM and a slight decrease 
in the binding was observed when higher concentrations of hemin-agarose (>3 mM) were 
added. The concentration of hemin-agarose needed to reach the saturation was relatively 
high. However, we have previously shown that 40 µM hemin displaces >90% of ABCB6 
bound to hemin-agarose [204] suggesting that the Kd observed using hemin-agarose is 
likely to be much higher than the actual Kd for free hemin. The agarose beads may be a 
limiting factor for the amount of ABCB6 molecule to bind to hemin-agarose requiring 
apparently much higher concentration to reach a saturation point. 
 
Even though functions of NBD and MSD are tightly coupled, how the changes in 
NBD are transmitted to MSD and vice versa has not been shown clearly because the 
structural data of a mammalian ABC transporter are lacking. Structural data on the 
soluble NBDs provided an insight into how ATPase sites are formed between two NBDs 
and the conformational changes that they undergo when bound to nucleotides [110, 111]. 
The structure of a sandwich NBD dimer and other biochemical data led to a substrate 
transport model that ATP binding induces a conformational change sufficient to release 
substrates [114]. The structure of nucleotide-bound bacterial ABC transporter Sav1866, 
which shows a significant sequence similarity to human ABCB subfamily members, 
shows an outward opening of TM helices [97]. The NBD is in a closed dimer and the 
cavity in the membrane created by TM helices is not accessible from the cytosol. 
Therefore, the cavity is suggested to represent the substrate translocation path into the 
extracellular space. The outward facing cavity of ATP-bound MDR1 has also been 
shown using electron microscopy [229, 230]. Binding of AMPPNP to ABCB6 results in a 
release of ABCB6 from hemin-agarose suggesting that ABCB6 undergoes 
conformational changes between a high affinity to a low affinity state for substrates 
depending on nucleotide binding status. A higher concentration of AMPPNP was 
required to release 50% of ABCB6 from hemin-agarose compared to ATP. However, the 
concentration used in this study (5 mM) to observe an effect is consistent with previous 
studies that showed 4 mM AMPPNP was required to bind to MRP1 NBD1 [227]. The 
condition this experiment was performed, room temperature, is not ideal for ATP 
hydrolysis and, therefore, the effect of ATP hydrolysis on the conformational changes 
should be minimal. Taken together, our results provide biochemical evidence that a 
substrate is released from ABC transporter upon nucleotide binding and support the ATP 
switch model. 
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CHAPTER 4.  ABCB6 CONTAINS AN N-TERMINAL ER EXIT SIGNAL THAT 
IS CONSERVED IN OTHER ABC TRANSPORTERS 
 
 
4.1. Introduction 
 
 ATP-binding cassette (ABC) transporters are involved in the ATP-dependent 
transmembrane movement of various compounds [2]. Their diverse physiological 
functions have been revealed because ABC transporter deficiencies lead to human 
diseases such as cystic fibrosis, Dubin-Johnson syndrome, X-linked sideroblastic anemia 
and ataxia and hyperinsulinemic hypoglycemia [2]. ABC transporters at the plasma 
membrane extrude endogenous compounds, but also protect cells by reducing the 
accumulation of toxic compounds. Moreover, ABC transporters are found in subcellular 
organelles and play key roles in biological processes such as heme biosynthesis, [Fe-S] 
cluster formation, and antigen presentation.   
 
ABC transporter localization specifically to the plasma membrane or to 
subcellular organelles suggests inherent signals within the transporter are required to 
ensure proper localization. However, among ABC transporters, it is difficult to identify a 
typical sequence or modification that affects all membrane transporters. For example, 
lack of ABCG8 glycosylation causes ER retention, and apical localization of ABCB11 
requires at least two out of the four N-glycosylation sites [133, 231]. In contrast, 
CFTR/ABCC7 membrane localization is independent of N-glyosylation [232].   
 
In the ER, several covalent post-translational modifications occur, which include 
signal sequence cleavage, N-glycosylation, and disulfide bond formation. Disulfide bonds 
are formed in the ER via the action of protein disulfide isomerase enzymes. If essential 
disulfide bond(s) are not formed, some proteins are retained in the ER [233] by a process 
referred to as “thiol retention” [234]. Thiol retention has been shown to regulate the ER 
exit of adiponectin [235] and IgM. If the free thiols in IgM are not oxidized by formation 
of disulfide bonds or by other means, then IgM does exit the ER [236, 237]. IgM egress 
from the ER can be manipulated by changing the cellular redox environment with thiol 
reductants (e.g. DTT or β-ME) [238]. 
 
We have previously shown that ABCB6 is a homodimeric porphyrin transporter, 
which through its localization at the mitochondrial outer membrane facilitates heme 
biosynthesis [204]. ABCB6’s high expression in human and murine fetal liver coincides 
with definitive erythropoiesis. As expected, ABCB6 is upregulated during differentiation 
of progenitor cells toward the erythroid lineage. This is consistent with the requirement 
for porphyrins in erythropoiesis as erythroid cells require a high heme production to 
ensure hemoglobin synthesis [176]. Furthermore, ABCB6 function is necessary to ensure 
efficient heme biosynthesis. Heme biosynthesis occurs in two compartments, and the 
energetic constraints of shuttling the anionic heme precursor, CPgenIII from the cytosol 
into the intermembrane space where the next enzyme in the pathway resides, make this a 
potential rate-limiting step that ABCB6 can overcome by transporting CPgenIII across 
the outer membrane [176].  
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While ABCB6 is a mitochondrial outer membrane protein, it is not clear how 
ABCB6 trafficks in the cells, what signals are required for the trafficking, or if these 
signals are required for function. In this study, we show that ABCB6 is modified by 
glycan addition at only one site. Moreover, ABCB6 trafficks through the ER to the Golgi, 
a process that requires the formation of a disulfide bond between two cysteines present at 
the N-terminus. Notably the ABCC subfamily members that insert their N-terminal into 
the ER lumen (e.g. ABCC1, C2, etc.) contain N-terminal cysteines that may form a 
disulfide bond.  The functional significance of these cysteines were revealed in 
SUR1/ABCC8, a plasma membrane K+ channel regulator [83]. We discovered a single 
mutation in this conserved cysteine in SUR1/ABCC8 from a patient with defective K+ 
channel function. As a consequence of this single point mutation in the conserved 
cysteines, SUR1/ABCC8 was incapable of trafficking to the plasma membrane. Our 
findings have uncovered a conserved N-terminal disulfide bond, which provides an 
important signal for ER exit of ABC transporters and suggests that alterations in the 
redox status of the ER can impact ABC transporter trafficking. 
 
 
4.2. Experimental Procedures 
 
 
4.2.1. Cell Culture 
 
NIH3T3 cells, Mel cells and K562 vector or ABCB6-Flag cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 4500 mg/L glucose 
supplemented with 10% FCS (HyClone, Logan, UT), 2 mM L-glutamine, 100 units/ml 
penicillin, and 100 ug/ml streptomycin (Gibco, Carlsbad, CA) in humidified atmosphere 
containing 5% CO2 at 37 ˚C. NIH3T3 cells were seeded on 6 well-clustered dishes (3 x 
105 cells/well) 24 hours prior to transfection, and then transiently transfected with 
expression plasmids (total of 1µg except for when otherwise indicated) using 
LipofectAMINE Plus (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocols. 
 
 
4.2.2. Site-Directed Mutagenesis 
 
Plasmids pcDNA3-hABCB6-Flag and pcDNA3.1-hABCB6-V5-His were 
designed to express human ABCB6 with a C-terminal tag, Flag or V5 respectively as 
previously described [204]. A point mutation was introduced into pcDNA3.1-hABCB6-
V5-His using a Quikchange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and 
primers (N447Q, sense, 5’-CGTGCTATGAACACACAGGAGCAAGCTACCCGGGC-
ACGAGCAGTG-3’, antisense, 5’- CACTGCTCGTGCCCGGGTAGCTTGCTCCTGT-
GTGTTCATAGCACG-3’; N498Q, sense, 5’-GCGCTTCACTGGTTTTACTACAACA-
GACCCAGAACCTGGTGATTG3’, antisense, 5’-CAATCACCAGGTTCTGGGTCTG-
TTGTAGTAAAACCAGTGAAGCGC-3’; N677Q, sense, 5’-CCCAAGACACTGTCCT-
CTTTCAAGACACCATCGCCGACAATATC-3’, antisense, 5’-GATATTGTCGGCGA-
TGGTGTCTTGAAAGAGGACAGTGTCTTGGG-3’; N775Q, sense, 5’-TCTGGCCAA-
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AGTCTGTGCCCAACGCACCACCATCGTAGTGGC-3’, antisense, 5’-GCCACTACG-
ATGGTGGTGCGTTGGGCACAGACTTTGGCCAGAG-3’; N6Q, sense, 5’-CTTGCC-
ATGGTGACTGTGGGCCAATACTGCGAGGCCGAAGGGCC-3’, antisense, 5’-GGC-
CCTTCGGCCTCGCAGTATTGGCCCACAGTCACCATGGCAAG-3’; C8S, sense, 5’-
GGTGACTGTGGGCAACTACTCCGAGGCCGAAGGGCCCGTGG-3’, antisense, 5’-
CCAC-GGGCCCTTCGGCCTCGGAGTAGTTGCCCACAGTCACC-3’; C26A, sense, 
5’-GCAGGATGGCCTGAGTCCCGCCTTCTTCTTCACGCTCGTGCC-3’, antisense, 
5’-GGCACGAGCGTGAAGAAGAAGGCGGGACTCAGGCCATCCTG-C-3’; C50A, 
sense, 5’-GCCTTGGTGCTGGCTCTTCCCGCTAGACGCCGGGAGCGG-CCCGC-3’, 
antisense, 5’-GCGGGCCGCTCCCGGCGTCTAGCGGGAAGAGCCAGCACCAAGG-
C-3’; C120A, sense, 5’-CTGGAGAGTCTGGCCGGCGCCGCTGGCCTGTGGCTGCT-
TGTCGTG-3’, antisense, 5’-CACGACAAGCAGCCACAGGCCAGCGGCGCCGGCC-
AGACTCTCC-AG-3’). All genes were thoroughly sequenced after mutagenesis. A point 
mutation was introduced into pcDNA3.1-hABCB6-N447Q-V5-His at N498 as described 
above to yield pcDNA3.1-hABCB6-N447,498Q-V5-His. The pcDNA3.1-hABCB6-Q4-
V5-His mutant was generated by introducing a point mutation into pcDNA3.1-hABCB6-
N447, 498Q-V5-His at N677 and then at N775. An additional mutation was introduced 
into pcDNA3.1-hABCB6-Q4-V5-His at N6 to generate pcDNA3.1-hABCB6-Q5-V5-His. 
pcDNA3.1-hABCB6-C8S,C26A-V5-His was generated by introducing a point mutation 
into pcDNA3.1-hABCB6-C8S-V5-His at C26. 
 
To generate truncated mutant constructs to determine the disulfide bond 
formation, point mutations were introduced into constructs pcDNA3.1-hABCB6-V5 at 
C50 and then at C120 using primers described above. And then the N-terminus of the 
mutant ABCB6 construct containing amino acids 1 to 210 with Flag tag at the C-terminus 
was amplified using primers (sense, 5’-GCCATGGTGACTGTGGGCAACTACTGCGA-
GGCCG-3’, and antisense, 5’-CCTACTTATCGTCGTCATCCTTGTAATCACGAAGT-
CCAGGGGCCCAGAG-3’) with the following condition (94˚C, 4 min, denaturing at 
94˚C for 30 sec, annealing at 56˚C for 30 sec, and reaction at 68˚C for 1 min for 30 
cycles). The PCR product was purified from agarose gel and TA-cloned into pCR2.1-
TOPO vector (Invitrogen). The inserts were sublconed into pcDNA3 using HindIII/XbaI 
sites to obtain pcDNA3-hABCB6-C50/120A-N1-210-Flag. 
 
 
4.2.3. Immunoblotting  
 
Twenty-four hours after transfection, cells were washed with PBS and then 
scraped into 1 ml cold PBS containing 1 x commercial protease inhibitor cocktail 
(complete EDTA free, Roche, Mannheim, Germany). Cells were pelleted by 
centrifugation at 1,000 x g for 4 min at 4˚C, and were resuspended in buffer A (50 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, and 1 x commercial protease inhibitor 
cocktail (complete, Roche)), and sonicated (three 10 sec pulses). Nonidet P40 (NP-40, 
final concentration of 1%) was added to solubilize the cells, followed by constant rocking 
for 60 min at 4˚C. Samples were then centrifuged at 17,000 x g for 15 min at 4˚C to 
remove cell debris. Protein concentration in the supernatant was measured by Bradford 
method (Protein Assay, Bio-Rad Laboratories Inc., Hercules, CA). The lysate was further 
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processed for either immunoblotting or glycosidase digestion. For immunoblotting, 
Laemmli sample buffer containing β-ME unless otherwise indicated (final concentration 
1x, Bio-Rad Laboratories Inc.) was added to the supernatant and the samples were 
fractionated on 7.5, 10 or 12.5% SDS-PAGE. Afterward, proteins were transferred to a 
nitrocellulose membrane (Amersham Biosiences). The blots were blocked with 10% skim 
milk in PBS-T and incubated with either anti-FLAG (M2 or polyclonal, Sigma), anti-V5 
polyclonal (MBL, Nagoya, Japan), anti-ABCB6 (serum), or anti-ABCB6 monolconal 
antibodies. The blots were washed with PBS-T, incubated with secondary antibodies 
(horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG F(ab’) fragment, 
Amersham Pharmacia Biotech., Liscataway, NJ), and immunoreactive proteins detected 
by using enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech.). 
 
 
4.2.4. Glycosidase Digestion 
 
Lysates were prepared as described above from NIH3T3, K562, or Mel cells. 
After denaturation in 1 x denaturing buffer (0.5% SDS, 1% β-marcaptoehtanol), the 
samples were incubated at 37˚C for 1 hr with or without PNGase F (New England 
Biolabs, Inc., Beverly, MA) in reaction buffer (50 mM Na2PO4 (pH 7.5) and 1% NP-40) 
according to the manufacturer’s recommended procedures. For EndoH digestion, the 
denatured samples were incubated with or without the enzyme in 50 mM sodium citrate 
buffer. 
 
 
4.2.5. Mitochondria Isolation 
 
K562 or Mel cells were pelleted, washed with PBS, and resuspended in 
resuspension buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl (pH 7.6), and 1 x 
protease inhibitor cocktail (Roche). After 10 min incubation on ice to allow the cells to 
swell, they were broken with type B Dounce homogenizer. 2.5 x membrane stabilizing 
buffer (525 mM mannitol, 175 mM sucrose, 12.5 mM Tris-HCl (pH 7.6), and 2.5 mM 
EDTA) was added to the homogenate to a final concentration of 1 x. The samples were 
centrifuged at 1,300 x g for 5 min at 4 ˚C to remove cell debris and nuclei. The 
supernatant was further centrifuged at 17,000 x g for 15 min at 4˚C to pellet 
mitochondria. 
 
4.2.6. Pulse Chase 
 
K562 vector or ABCB6-Flag cells (~ 2 x 106 cells) were washed with warm 1 x 
Hank’s buffer and incubated in labeling media (DMEM without L-methionine, L-cysteine 
(Cellgro, Manassas, VA), 10% dialyzed FBS (Hyclone), 2 mM L-glutamine) containing 
0.1 mCi/ml [35S] (Trans 35S-label,[35S] L-Methionine, [35S] L-Cysteine, 1175 
Ci/mmol, MP Biomedicals, Inc. Irvine, CA) for 20 min at 37˚C. Cells were then washed 
once with chase media (complete DMEM supplemented with 2 mM L-methionine and L-
cysteine) and chased for times indicated in the figures. At the end of each chase time 
interval, cells were washed with cold PBS, pelleted, flash frozen in liquid N2 and stored 
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at -80˚C until use. Cells were lysed in NP-40 lysis buffer (50 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 0.5% deoxycholate, and 0.5% NP-40) for 15 min on ice and cell debris was 
removed by centrifugation at 15,000 x g for 10 min at 4˚C. The lysate was incubated with 
20 µl anti-Flag M2 antibody conjugated agarose (50% slurry, Sigma) for 2 hr at 4˚C with 
constant rotation. The beads were washed three times with Washing buffer (50 mM Tris-
HCl (pH 7.5), 400 mM NaCl, 0.5% deoxycholate, 0.5% NP-40) and then resuspended in 
2 x Laemmli SDS sample buffer containing β-ME. Samples were separated by SDS-
PAGE. The gel was fixed, stained by Coomassie G-250 (GelCode Blue, Pierce), 
incubated with Amplify fluorographic reagent (Amersham, GE Healthcare) and was 
dried. [35S]-labeled proteins were detected by autoradiography. 
 
 
4.2.7. Glycosylation Site Prediction 
 
To search for potential N-glycosylation site(s) in ABCB6 sequence, PROSITE 
motif search, which scans for a consensus motif N-X-S/T-X where X can be any amino 
acid except for proline, was performed (http://www.predictprotein.org, accessed Oct. 13, 
2004). 
 
 
4.2.8. Detection of SUR1 
 
 A series of SUR1/ABCC8 mutant constructs were generated where Cys6 and 
Cys26 were singly or doubly mutated to alanine or serine. Rest of the 27 cysteine 
residues were mutated to either alanine or serine in these constructs. COSm6 cells were 
co-transfected with the various SUR1 constructs with KIR6.2. SUR1 was affinity labeled 
with [125I]-azidoglibenclamide, fractionated on SDS-PAGE, and detected by 
autoradiography.  
 
 
4.3. Results 
 
 
4.3.1. Both Endogenous and Exogenous ABCB6 Are Glycosylated 
 
Glycosylated proteins, which are synthesized in the ER, are often observed as 
broad or smeared bands on immunoblotting. Although ABCB6 is a mitochondrial 
protein, which are typically not glycosylated, we tested if it was modified by N-linked 
glycans because ABCB6 appeared as a broad band on immunoblots. Crude mitochondrial 
preparations from either human erythroleukemia K562 or murine erythroleukemia Mel 
cells were treated with either PNGase F to remove high mannose and complex glycans 
from asparagine residues or Endo H, which only reacts with high mannose glycans found 
on proteins as long as they remain in the ER. Immunoblot analysis (using both an anti-
ABCB6 antiserum and a monoclonal antibody we developed to a conserved epitope) 
revealed faster migration of both human and murine ABCB6 after PNGase F but not 
Endo H treatment (Fig. 4.1.). The PNGase F sensitivity and Endo H resistance 
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Figure 4.1. ABCB6 is glycosylated.  
Crude mitochodria preparations from A) K562, human erythroleukemia or B) Mel, 
murine erythroleukemia cells were treated with PNGase F or Endo H and ABCB6 was 
detected by immunoblotting. Cell lysates from C) K562 cells expressing vector or 
ABCB6-Flag or D) NIH3T3 cells transiently transfected with ABCB6-V5 were treated 
with PNGase F and analyzed by immunoblotting. E) ABCB6 was no longer glycosylated 
when K562 cells expressing ABCB6-V5 were treated with tunicamycin. F) Pulse chase 
assay using K562 cells expressing ABCB6-Flag showed the glycosylated ABCB6 at 60 
min. 
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Figure 4.1. (continued). 
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demonstrate that both human and murine ABCB6 are glycosylated and traffick through 
the ER to the Golgi.  
 
We next tested whether epitope-tagged human ABCB6 exhibited the same pattern 
of glycosidase sensitivity. We found that the ABCB6, transfected into K562 and NIH3T3 
cells, was PNGase F sensitive (Fig. 4.1.). These results demonstrate that epitope-tagged 
ABCB6 trafficks like endogenous ABCB6. Moreover, this processing pathway is 
indistinguishable between erythroid and non-erythroid cells. The extent of glycosylation 
does differ between species with ABCB6 in human cells showing multiple bands whereas 
ABCB6 in mouse cells shows only one discrete band. To understand the pathway leading 
to ABCB6 glycosylation, we used two experimental approaches: pulse chase labelling 
and treatment with tunicamycin (TNM), an inhibitor of glycan synthesis in the ER. 
Treatment of K562 cells stably expressing ABCB6-V5 with TNM abolished the high 
molecular weight bands (Fig. 4.1.). Tunicamycin sensitivity of ABCB6 glycan 
modification confirms that ABCB6 trafficks through the ER. We performed a pulse chase 
experiment to follow the maturation of ABCB6. The CHO-TRex system was used 
previously to transiently express ABCB6 in order to demonstrate ABCB6-activated de 
novo porphyrin biosynthesis [204]. Therefore, given that the exogenous ABCB6 activates 
heme biosyntheis like the endogenous protein, exogenous ABCB6 was likely to proceed 
via a processing pathway similar to the endogenous one in this system. CHO cells 
harboring the reverse tet operator were transfected with pcDNA4-ABCB6-Flag, treated 
with tetracycline, and then pulsed for 20 min with [35S]-Cys/Met labeling mixture in 
media lacking Cys/Met. Cells were collected after various chase intervals, and 
immunoprecipitated [35S]-labeled ABCB6 was separated by SDS-PAGE and detected by 
autoradiography. Slower migrating forms of ABCB6 were detected at 60 and 120 min 
after the pulse, which are likely to correspond to further modification of the N-linked 
glycans in the Golgi (Fig. 4.1.). 
 
 
4.3.2. ABCB6 Is Glycosylated at an Atypical N-X-C Site 
 
Potential N-glycosylation site(s) in ABCB6 sequence were identified using 
PROSITE motif search (http://www.predictprotein.org, [239]), which scans a consensus 
glycosylation motif N-X-S/T-X (X can be any amino acid except for proline [240]). The 
search results revealed four potential glycosylation sites in human ABCB6, which are 
also conserved in mouse Abcb6 (Fig. 4.2.A). We have previously shown that the C-
terminus of ABCB6 (containing the nucleotide binding domain) resides in the cytoplasm 
[204]; therefore, Asn677 and Asn775 are unlikely targets for glycosylation because they 
will not face the site of glycosylation in the ER lumen. Nevertheless, each asparagine (N) 
residue was individually substituted with glutamine (Q) to develop four ABCB6 mutant 
constructs. Further, a double asparagine mutant where both Asn447 and Asn498 were 
substituted with glutamine residues was generated in the event more than one 
glycosylation site is used. All five ABCB6 asparagine mutants contained a V5 epitope tag 
at the C-terminus and were transiently expressed in NIH3T3 cells. The migration patterns 
of ABCB6 asparagine mutants were assessed after PNGase F treatment (Fig. 4.2.B). 
Unexpectedly, individual or double ABCB6 asparagine mutants showed the same  
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Figure 4.2. ABCB6 is glycosylated only at the atypical N-X-C site.  
A) Four consensus and one atypical glycosylation sites in human ABCB6. B, C) 
Asparagine residues in the consensus or the atypical (N6Q) sites were substituted with 
glutamine residues. NIH3T3 cells were transiently transfected with B) single mutants and 
C) Q4 mutant in which all four Asn residues were mutated, or D) single mutant N6Q or 
Q5 in which all five Asn residues were mutated with glutamine. Proteins were subjected 
to glycosidase treatment and analyzed by immunoblotting using anti-V5 antibody. The 
presence of glycans was determined by the mobility shift in the immunoblotting. 
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Figure 4.2. (continued) 
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migration pattern as the wild-type protein, in that they migrated faster after treatment 
with PNGase F, which indicates these asparagine mutations do not change ABCB6 
glycosylation. Therefore, to rule out the possibility of multi-site glycosylation, all four 
asparagine residues in the consensus glycosylation motifs were substituted with 
glutamine residues (designated as Q4 mutant). Surprisingly, Q4 behavior was identical to 
the wild-type protein such that the faster migrating band (immature ABCB6) was only 
seen when treated with PNGase F (Fig. 4.2.). These results indicate that other 
glycosylation site(s) must exist. 
 
An extensive review of the available literature revealed five proteins that use a 
cysteine residue instead of the typical serine or threonine at the glycosylation site (N-X-
C) [241-245]. These proteins are typically secreted proteins. However, because these 
proteins have other typical glycosylation sites and the N-X-C motif represents a minority 
of the glycosylation sites, its functional significance remains unknown. The five proteins 
are: Protein C (1/4), von Willebrand factor (1/12), fetal antigen I (2/3), transferrin (1/3), 
and CD69 (1/2), and the proportion of N-X-C motifs out of the total number of 
glycosylation sites is indicated in the parentheses. Examination of the ABCB6 sequence 
revealed one atypical glycosylation motif near the N-terminus, N-Y-C starting at position 
6 (Fig. 4.2.). To test the possibility that this site was used in ABCB6, the asparagine 
residue at position 6 was substituted with a glutamine residue in both wild-type and Q4 
constructs to generate N6Q and Q5 ABCB6 constructs respectively. The ABCB6 
asparagine mutants were transiently transfected into NIH3T3 cells, treated with PNGase 
F and analyzed by immunoblotting using anti-V5 antibody (Fig. 4.2.). Both Q5 and N6Q 
migrated faster than the wild-type ABCB6-V5 and their mobility was unaffected by 
PNGase F treatment and identical to the PNGase F-treated wild-type protein. These 
findings indicate that ABCB6 uses the N-X-C motif as its sole glycosylation site. 
 
Generally, ABC half transporters contain six TM helices; however, the unique 
glycosylation site at the N-terminus and the cytoplasmic localization of the C-terminus 
allowed us to develop a topological model that contain more than six TM helices for 
ABCB6. Accordingly, programs such as TopPred and TMHMM predicted ABCB6 to 
contain nine TM helices [218, 219], while HMMTOP and SOSUI predicted 11 and 10, 
respectively [220, 246, 247]. TopPred, TMHMM, and HMMTOP predicted that the sole 
glycosylation site is protruded into the ER lumen. The absence of glycans at Asn677 and 
Asn775 is consistent with the C-terminus in the cytoplasm, which is in agreement with 
our previous biochemical findings [204]. These results indicate that N- and C-termini are 
on the opposite sides of the membrane and suggest that ABCB6 contains an odd number 
of TM helices. The lack of glycosylation at the consensus sites Asn447 and Asn498 
suggests that these residues are not accessible to the glucosyltransferase (although not all 
N-X-S/T sites are used in secretory proteins), and, therefore, are likely to reside in the 
cytoplasm. Only the predictions from HMMTOP and TMHMM satisfy all these criteria, 
in which HMMTOP model contains extra two TM helices (248-271A.A. and 392-
326A.A.) in place of a large cytoplasmic loop in the TMHMM prediction (Fig. 4.3.). It is 
notable that we have identified a form of ABCB6 that lacks amino acids 240 to 289, 
which we have previously shown is incapable of binding heme. 
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Figure 4.3. ABCB6 is predicted to contain 9 TM helices.  
Schematic drawing of membrane topology of ABCB6. TM helices in ABCB6 amino acid 
sequence (NP 005680.1) were predicted using A) HMMTOP or  B) TMHMM. Topology 
model representation was generated by TMRPres2D ([248] 
http://bioinformatics.biol.uoa.gr/TMRPres2D). The additional luminal loop in HMMTOP 
is boxed. C) Glycosylation site insertion shows that TMHMM prediction appears to be 
valid. N-glycosylation sites were introduced into N6Q mutant lacking inherent 
glycosylation site and the mutants were analyzed for glycosylation status using PNGase 
F. 
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In order to validate the membrane topology of ABCB6, consensus glycosylation 
sites were introduced into the non-glycosylated form of ABCB6, ABCB6-N6Q at 
positions V290T and L292N). If HMMTOP prediction is valid, then V290T and L292N 
mutants, which contain perfect consensus sites for glycosylation at Asn288 or Asn290 in 
the additional luminal loop predicted only in HMMTOP, will be glycosylated. These 
ABCB6 constructs along with an unmodified ABCB6 were transiently expressed in 
NIH3T3 cells and lysates were treated with PNGase F. The PNGase F sensitivity of each 
mutant was analyzed by immunoblotting (Fig. 4.3.). An additional ABCB6 control was 
developed in ABCB6-N6Q where Glu236 was substituted with asparagine residue 
(Q236N) to make a consensus glycosylation site in the predicted cytoplasmic loop. 
Accordingly, this mutant ABCB6 was not glycosylated. Moreover, V290T and L292N 
were not glycosylated as only the fast migrating band was observed even in untreated 
samples. Because these sites were not accessible to glucosyltransferase, they are likely to 
reside in the cytoplasm, favoring the membrane topology predicted by TMHMM.   
 
 
4.3.3. Cysteine Is Dispensable for Glycosylation but Is Critical for ER Exit 
 
 Since ABCB6 is only glycosylated at the atypical glycosylation motif, we next 
tested if the cysteine in N-X-C was required for glycosylation of ABCB6. The cysteine 
residue was substituted with a serine residue to make a consensus glycosylation site (N-
X-S, labeled C8S). The C8S mutant was transiently expressed in NIH3T3 cells and 
glycosylation state was evaluated by PNGase F treatment. The ABCB6-C8S was PNGase 
F sensitive indicating that the cysteine residue is not required for glycosylation (Fig. 
4.4.). As a control, we showed that glycine substitution to form a non-consensus site 
caused a loss of glycosylation, which underscores the importance of having either the 
consensus N-X-S/T or N-X-C motif for glycosylation. Unexpectedly, C8S mutant was 
Endo H sensitive indicating that this mutant failed to exit the ER (Fig. 4.4.). 
 
 Despite glycosylation, the retention of ABCB6-C8S in the ER suggested this 
residue might play a role in ER to Golgi trafficking. We found that Cys8 is highly 
conserved among human, chimpanzee, mouse, rat, and zebrafish (Fig.4.5.A ) suggesting a 
conserved function of this residue across species. Notably, the asparagine residue for 
glycosylation in not conserved in zebrafish. This analysis also revealed a conserved 
downstream cysteine residue at position 26. Based on our computer-assisted analysis, 
both TMHMM and HMMTOP predict Cys26 would be in the ER lumen. To determine if 
Cys26 played a role in ER to Golgi trafficking, we mutated the cysteine residue to alanine 
or serine residue in the wild-type and C8S mutant. Single mutants, C26A and C26S, were 
both PNGase F and Endo H sensitive like the trafficking-impaired ABCB6-C8S (Fig. 
4.5.B). Furthermore, the mutant lacking both cysteine residues, C8S/C26A and C8S/26S, 
were Endo H sensitive. These results indicate that both Cys8 and Cys26 are critical for 
the ER exit of ABCB6. We hypothesized that we could rescue trafficking defect by 
inserting a cysteine residue just downstream from C8S; therefore, a cysteine residue was 
inserted between Glu9 and Ala10 to create C8S/C10in mutant. However, this construct 
failed to acquire Endo H resistance, which indicates that the space between the two 
cysteines is important to ER exit of ABCB6 (Fig. 4.5.C). 
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Figure 4.4. Cys8 is dispensable for glycosylation but is critical for ABCB6 ER exit.  
A) Cys8 is substituted with serine or glycine and the mutant proteins were transiently 
expressed in NIH3T3 cells. The glycan modification of the mutants was determined by 
PNGase F sensitivity and analyzed as in Fig. 4.3. ABCB6 is still glycosylated when C8 is 
substituted with Ser to make a consensus motif. B) Total lysates from NIH3T3 cells 
expressing either wild type ABCB6, C8S, or N6Q mutants were analyzed for PNGase F 
and Endo H sensitivity. 
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Figure 4.5. Both Cys8 and Cys26 are required for ER exit of ABCB6. 
A) Cys8 and Cys26 are highly conserved among species. Amino acid sequence alignment 
of ABCB6 from human, mouse, rat, dog, chimpanzee, and zebrafish. Only the N-
terminus of each sequence is shown. Dog ABCB6 contains a long additional N-termius 
that is omitted from this figure. Red arrowhead indicates the N-glycosylation site, 
whereas black arrowheads indicate the conserved cysteine residues. B) Cys26 is 
substituted with alanine or serine on wild-type or C8S mutant. The mutants were 
analyzed for glycosidase sensitivity as in Fig. 3. Cys26 mutants and double mutants also 
failed to exit the ER. C) Cysteine residue was inserted between position 9 and 10 in C8S 
mutant to create a possible site for disulfide bond formation with Cys26.  
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4.3.4. Cys8 and Cys26 Form Intramolecular Disulfide Bond 
 
 Because two conserved cysteine residues facing the ER lumen are critical for the 
ER exit of ABCB6, we next tested if they formed an intramolecular disulfide bond. 
Intramolecular disulfide bonds are detected by mobility shifts of bands in non-reducing 
compared to reducing SDS-PAGE, because the disulfide bonds produce protein 
compaction resulting in a faster migration under non-reducing conditions compared to the 
reduced ones. The extent of the band shift is positively correlated with the distance 
between the two participating cysteine residues. We reasoned that the minimal number of 
residues separating the two conserved cysteines in ABCB6 (17 A.A.) would produce a 
barely detectable band shift in a protein with a molecular mass of 94 kDa. Therefore, we 
developed an ABCB6 chimeric protein that contained 210 amino acids from the N-
terminus fused to GFP. The mutant exhibited PNGase F sensitivity and Endo H 
resistance, the pattern similar to full length ABCB6 (Fig. 4.6.B). According to the 
membrane topology prediction, N1-210 mutant spans the membrane five times and places 
the tagged-C-terminus in the cytoplasm (Fig. 4.6.A). To distinguish the band shift better, 
the same truncation mutant was tagged with a Flag epitope instead of a bulky GFP 
molecule. This construct has a further advantage because the different forms of non-
glycan and glycan modified ABCB6 can be identified. In order to eliminate any 
contaminating effects from the other cysteine residues in the construct (inter- or 
intramolecular disulfide bonds via other cysteines), Cys50 and Cys 120 were substituted 
with alanine residues in the mutant construct (ABCB6N1-210-Flag and ABCB6-
C50/120AN1-210-Flag).  
 
Three distinct bands were readily seen upon analyzing ABCB6C50/120AN1-210-
Flag by immunoblotting (Fig. 4.6.C). Glycosidase assays allowed us to determine the 
identity of each band: the slowest migrating band (a) is PNGase F sensitive and Endo H 
resistant band and represents the mature ABCB6 with complex glycans, the middle band 
(b) is PNGase F and Endo H sensitive and represents ER-type ABCB6 with high 
mannose modification, and the fastest migrating band (c) contains no glycans and is, 
therefore, the immature ABCB6. The size of the truncated ABCB6 allows separation of 
the very distinct forms of ABCB6 unlike the full-length ABCB6.  
 
We next transfected ABCB6N1-210-Flag and ABCB6-C50/120AN1-210-Flag into 
K562 cells and analyzed the proteins in the presence or absence of reducing agent DTT. 
Cells were treated with and harvested in the presence of alkylating agent NEM to prevent 
spontaneous disulfide bond formation. ABCB6 samples ran in the absence of DTT 
migrated faster compared to the reduced samples suggesting that ABCB6 has different 
folding under non-reducing conditions due to a disulfide bond (Fig. 4.6.D). 
 
 
4.3.5. N-terminal Cysteine Residues Are Conserved in the Long MRPs       
 
The “core” unit of ABC transporters consists of a membrane-spanning domain 
(MSD) with six TM helices and a nucleotide-binding domain (NBD) [87]. Functional 
transporters require two sets of such core units; full transporters contain two units in  
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Figure 4.6. N-terminus of ABCB6 contains a disulfide bond. 
A) Schematic drawing showing that ABCB6N1-210 mutant spans the membrane five times 
based on TMHMM prediction with GFP in the cytoplasm. B) ABCB6N1-210 truncated 
mutant is processed similarly to the full-length protein. Typical results from glycosidase 
assays are shown. Mouse ABCB6 construct with a C-terminal GFP were used for these 
experiments. N1-210 showed very low Endo H sensitivity. C) ABCB6-C50/120AN1-210-
Flag was analyzed as in Fig. 4.3. Identity of each band is described in the text. D) 
ABCB6N1-210-Flag and ABCB6-C50/120AN1-210-Flag were expressed in K562 cells. K562 
cells were treated with NEM for 10 min and then the lysates were prepared in the 
presence of NEM. Samples were separated on 12.5% SDS-PAGE with or without 
reducing agent DTT and analyzed by immunoblotting.  
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tandem in a single polypeptide and half transporters with one such unit either need to 
homo- or hetero-dimerize. Since most ABC transporters contain an even number of TM 
helices (six in one MSD), both N- and C-termini reside in the cytoplasm. Some members 
of ABCC subfamily, however, contain additional MSD with 5 TM helices N-terminal to 
the MSD1 placing the N-terminus at the luminal or extracellular side [249]. Therefore, 
we investigated whether the N-terminal cysteine residues found in ABCB6 were 
conserved in some of these long MRPs. The alignment of amino acid sequence from 
ABCC1, C2, C3, C6, C8, C9, and B6 using clustal V showed that the two cysteines are 
conserved in all of them with a slight variation in the distance between two residues (17 
to 25 amino acids, Fig. 4.7.).  
 
SUR1/ABCC8 is a K+ channel regulator involved in modulating insulin secretion 
at the plasma membrane. In collaboration with Dr. Joseph Bryan, we isolated a mutant 
SUR1/ABCC8 where the conserved cysteine residue is mutated from a patient with 
defective K+ channel function, and therefore, with aberrant insulin secretion. To test 
whether the Cys mutant SUR1/ABCC8 was also ER retained as seen in ABCB6, we 
generated mutant constructs where Cys8 or Cys26 is mutated. The remaining 27 cysteine 
residues have been substituted with alanine or serine residues. The mutant SUR1 proteins 
were co-expressed with K+ channel, KIR6.2 in Cosm6 cells and were labeled with [125I]-
azidoglibenclamide. Proteins were fractionated by SDS-PAGE and the mature 
glycosylated SUR1 was identified by a lower mobility on the gel. The presence of the 
mature glycosylated SUR1 correlated with its surface expression (data not shown). As 
reported previously, mature form of SUR1 was observed only when KIR6.2 was co- 
expressed. Notably, the mature form of SUR1 was absent when one or both of the 
conserved cysteine residues were substituted with alanine or serine residues (Fig. 4.7.).   
 
 
4.4. Discussion 
 
 
4.4.1. N-Terminal Disulfide Bond Regulates ER Exit of ABC Transporters 
 
The mitochondrial membrane localization of the porphyrin transporter ABCB6 
has been shown by three independent studies [171, 204, 250]. Additionally, we, and 
others, have shown that ABCB6 specifically localizes to the mitochondrial outer 
membrane [204, 250]. Nonetheless, how ABCB6 reaches the mitochondrial outer 
membrane is important to understanding its function. An important key was our finding 
that ABCB6 is modified by glycan addition. Moreover, ABCB6 utilizes a single unique 
glycosylation site that is conserved among mammalian ABCB6, but heretofore only 
found in secreted proteins. This unique glycosylation site led to the identification of two 
conserved cysteine residues that are found in many ABC transporters and mutation within 
one ABCC family member (SUR1/ABCC8) is the genetic basis for the loss of function 
due to impaired membrane trafficking. 
 
In this study, we demonstrate that the two cysteine residues in the N-terminus of 
ABCB6 and SUR1 are an important ER exit signal. Substitution of cysteine residues in 
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Figure 4.7. N-terminal cysteines are conserved in long MRPs and regulate 
trafficking. 
A) Amino acid sequence alignment of ABCC1, C2, C3, C6, C8, and C9 is shown. 
Conserved cysteine residues are boxed in red and glycosylation sites are boxed in green. 
B) SUR1/ABCC8 constructs containing mutations at Cys6 and/or Cys26 were co-
expressed with KIR6.2 in COSm6 cells. SUR1 was labeled with [125I]-
azidoglibenclamide, fractionated on SDS-PAGE, and detected by autoradiography. 
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either ABCB6 or SUR1 with either serine or alanine at conserved positions leads to ER 
retention. This finding suggested one of the two related possibilities: i) the disulfide bond 
formation between ABCB6 Cys8 and Cys26 provides a loop that is a signal for ER exit or 
ii) a reduced cysteine(s) is a signal for ER retention. We favor the former idea because 
while single cysteine mutants are retained, double mutations of Cys8 and Cys26 that have 
no cysteine also results in a dramatically impaired ER exit. We confirmed that the N-
terminus of ABCB6 forms an intramolecular disulfide bond between Cys8 and Cys26 by 
showing that the chimeric ABCB6N1-210-Flag migrated faster under non-reducing 
conditions. These results indicate that disulfide bond-dependent folding occurs in the N-
terminus. Further support for a specific disulfide loop in ABCB6 being required for ER 
exit is the finding that an insertion of a cysteine residue at position 10 does not rescue 
trafficking defect of ABCB6-C8S mutant.  
 
The ER exit signal, which ABCB6 employs, appears to be different from that of 
the thiol retention mechanism, where exposed thiols are recognized by ER protein(s) as a 
retention signal [234]. First, most of the proteins that are regulated by thiol retention form 
intermolecular disulfide bonds [234] unlike ABCB6 where an intramolecular bond is 
formed. Second, in thiol retention, loss of the cysteine residue involved in the disulfide 
bond formation usually results in an increased secretion presumably by a lack of 
interaction with ER resident protein(s) that normally results in the ER retention [235, 
236]. On the other hand, in ABCB6, lack of a disulfide bond due to mutations of both 
cysteine residues involved does not rescue the defective ER exit. The disulfide loop may 
act as an ER exit signal via two possibilities: i) chaperone proteins dissociate upon the 
“disulfide-bonded loop” formation as a result of loss of a cysteine-independent binding 
site or ii) the structural change caused by the disulfide-bonded loop may provide a 
binding site for other chaperone proteins. At this point, these two possibilities have not 
been verified and are subject for future studies.  
 
Like ABCB6, the N-terminal cysteines required for ER exit are found in ABCC 
subfamily members that contain an N-terminus that inserts into the ER and is 
glycosylated (long MRPs; ABCC1, C2, C3, C6, C8, and C9) [249]. It is notable that non-
functional ABCC8/SUR1 from a hyperinsulinemic hypoglycemia patient had a single 
point mutation in in this conserved cysteines. This single mutation disrupted the 
potassium channel function in a hyperinsulinemic hypoglycemia patient. The mutant 
SUR1/ABCC8 is ER retained as shown by a lack of mature glycosylated SUR1/ABCC8. 
Thus, the N-terminal cysteines found in ABCC8/SUR1 also serve as an ER exit signal, 
most likely by through the formation of a disulfide bond. Further support for the role of 
the N-terminus is found in studies where the N-terminus of ABCC1 and ABCC2 localize 
to the plasma membrane in the absence of rest of the protein [251, 252] and ABCC1 
lacking this region (MSD0) has reduced cell surface expression [252]. These results 
further support our findings that the N-terminus, which contains the cysteines, is essential 
for trafficking of ABCC family members that insert their N-terminus in the ER. 
However, disulfide bond formation may be important in other ABC transporters [233]. In 
ABCG2, Cys592 and Cys608 form an intramolecular disulfide bond [253]. It is notable 
that the spacing between these cysteines is 16 amino acids, which is close to the 
separation conserved in ABCB6 and the ABCC family members. The ABCG2 double 
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cysteine mutant, C592/608A, lacked BODIPY-prazocin efflux activity and was expressed 
at a very low level on the cell surface. These results lend further support to our findings 
that the formation of intramolecular disulfide bond is a critical component of ER exit for 
many ABC transporters.  
 
 
4.4.2. ABCB6 Is Processed in the ER and Golgi 
 
In present study, we show that the mitochondrial protein, ABCB6 contains glycan 
modifications, which reveal trafficking from the ER to the Golgi. The presence of 
glycoproteins in mitochondria has been previously shown although the trafficking of such 
glycoproteins to mitochondria from the ER is not fully understood [254]. Translocation 
from the mitochondria to the ER was suggested when hepatitis C virus core protein 
showed either ER or mitochondrial localization [255]. The core protein localized to the 
ER when highly expressed by the CMV promoter but showed mitochondrial localization 
when expressed at much lower levels from a tetracycline-regulated promoter [255]. 
Interestingly, both the hepatitis C virus core protein and human cytomegarovirus UL37 
glycoprotein, another viral protein, localize to the ER prior to the mitochondrial 
translocation [256]. However, these studies do not provide insight into how ABCB6 
moves from the Golgi to the mitochondria.  
 
The N-glycosylation site in ABCB6 is unique because a cysteine residue (N-X-C) 
is substituted instead of a serine or threonine as found in most glycoproteins [240]. The 
atypical N-X-C motif has been reported only in five other proteins [241-245]. However, 
the functional role of this atypical motif is unknown because these proteins contain 
typical glycosylation sites, which might mask the function of the atypical site. We show 
that the cysteine residue in ABCB6 is not required for glycosylatin because substitution 
with a serine residue in the N-glycosylation motif does not affect ABCB6 glycosylation. 
Nontheless, analysis of ABCB6 from different species reveals that the asparagine residue 
is not conserved in zebrafish whereas the cysteine residue is. This suggests that genomic 
sequence upstream of the codon encoding the conserved cysteine residue acquired an N-
glycosylation site in mammals.  
 
Our study suggests ABCB6 topology is different from other half transporters. We 
have previously shown that the C-terminus of ABCB6 is localized to the cytoplasm 
[204]. The ER luminal localization of the N-terminus of ABCB6 indicates a protein with 
an odd number of TM helices which places the N and C-termini on the opposite sides of 
the ER membrane. This finding eliminated the proposed ABCB6 topological model with 
an even number of TM domains [250]; however, it could not distinguish if ABCB6 had 
nine TM helices (predicted by TMHMM) or 11 TMs (predicted by HMMTOP). To 
reconcile these two models, we inserted artificial glycosylation sites. The TMHMM 
membrane topology reveals the presence of a large cytoplasmic loop 3 (amino acids 206-
382). Interestingly, the naturally occurring ABCB6 splice variant, termed PRP, lacks 50 
amino acid residues within this loop. Since PRP does not bind to hemin-agarose as 
assessed by pull-down assays [204], we speculate that this loop may be a heme-binding 
domain.  
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4.4.3. Physiological Implication of the N-Terminal Disulfide Bond   
 
 The ABC transporters play important biological roles and provide the means to 
regulate the concentration of toxic xenobiotics and metabolites. To fine tune their arrival 
at their destination, both cis and trans mechanisms must be available to the cell. Our 
studies show that among many ABC transporters, formation of a disulfide bond between 
two conserved cysteines is essential for ER exit. Intramolecular disulfide bonds have 
been implicated in the post-trans Golgi network sorting of the secretory proteins, 
although the effect of DTT on the sorting of proteins was protein and cell type dependent 
[257]. For choromograin B, a secretory protein found in many endocrine cells and 
neurons, an N-terminal disulfide bond (Cys16 and Cys37) has been shown to play an 
important role in sorting into regulated secretory granules rather than constitutive 
secretory granules [257]. Although the disulfide bond we identified in this study 
determines the ER to Golgi movement, unlike chromograin B, the use of disulfide bonds 
as a sorting signal underscores the importance of proper post-translational modifications 
for protein trafficking. 
 
Interestingly, our data suggest that in a condition where the disulfide-bonded loop 
does not form, ABCB6 will be ER retained and imply that this occurs for other ABC 
transporters. In the oxidized environment of ER lumen, the ratio of oxidized to reduced 
glutathione (GSSG and GSH, respectively) is much higher compared to that of the 
cytoplasm and the glutathione acts as buffer to maintain the redox state. Several 
pathophysiological conditions such as aging are known to accompany changes in the 
cellular redox state, mostly to the oxidative state. While oxidative stress has been 
reported in diabetes, a reductive shift was observed in the microsomal redox status in rats 
with streptozotocin-induced diabetes [258]. Our results suggest that the ditribution 
patterns of functional ABC transporters may be altered in conditions where the ER redox 
status is shifted.  
 
The K+ channel (KIR) and its regulator, SUR1/ABCC8, require oligomerization to 
properly target the cell surface [259]. The newly identified conserved cysteines and 
presumably the disulfide-bonded loop in SUR1 adds another layer of checkpoint to 
ensure that only properly modified proteins leave the ER. While it is difficult to identify 
an universal signal for the sorting and trafficking of all ABC transporters, a small 
disulfide-bonded loop appears necessary for ER egress of a group of ABC transporters.  
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CHAPTER 5.  DISCUSSION 
 
   
The ABC transporters regulate the transmembrane movement of various 
compounds in an ATP-dependent manner [2]. At the plasma membrane, ABC 
transporters provide an important barrier to protect cells and tissues from the 
accumulation of toxic compounds; however, their ability to exclude different classes of 
drugs is the basis for many MDR phenotypes in tumor cells [53]. The physiological roles 
of ABC transporters extend beyond the barrier function and their importance in many 
biological processes is highlighted by their link to several pathophysiological conditions. 
For example, mutations in the ABC genes are the genetic basis for many human disorders 
including cystic fibrosis, Dubin-Johnson syndrome, immunedeficiency, and X-linked 
sideroblastic anemia and ataxia [2]. Although deficiencies of functional ABC transporters 
in the humans and the animal models revealed diverse physiological roles of ABC 
transporters, there are still many ABC proteins with unknown physiological functions. A 
relatively uncharacterized ABC transporter, ABCB6, is a mitochondrial half transporter 
with a possible role in iron homeostasis [171]. These previous findings, coupled with our 
findings that ABCB6 is highly expressed in the site of definitive erythropoiesis and its 
expression is coordinated with heme biosynthesis, prompted us to determine its role in 
heme biosynthesis. Our results that ABCB6 binds to various porphyrins, shows CPIII-
stimulated ATPase activity, and mediates ATP-dependent heme uptake into mitochondria 
all support our hypothesis that ABCB6 is a porphyrin transporter [204]. Moreover, 
ABCB6 is ideally located on the mitochondrial outer membrane to transport an anionic 
heme precursor, CPgenIII, into the intermembrane space where the next enzyme in the 
pathway resides. Indeed, overexpression of ABCB6 accelerates de novo porphyrin 
biosynthesis suggesting that ABCB6 facilitates the process by overcoming the 
energetically unfavorable transmembrane movement of porphyrins. By using a hemin-
agarose pull-down assay we developed, we demonstrated that ATP binding to ABCB6 is 
sufficient to induce a conformational change, which lowered its affinity for its substrate. 
Our results are in agreement with a recently published structural data of nucleotide-bound 
bacterial ABC protein. Three other mitochondrial ABC transporters have been shown to 
reside in the inner membrane, and thus, ABCB6 is the only one to localize on the outer 
membrane reported so far. The mitochondrial outer membrane localization has later been 
shown by a different group confirming our results [250]. However, recent studies report 
ABCB6 localization on different cellular membranes including the plasma membrane, 
Golgi, and vesicles [250, 260, 261]. Therefore, how ABCB6 trafficks intracellularly has 
been poorly understood. Our results here demonstrate that ABCB6 contains Endo H 
resistant glycans, which indicates ER to Golgi movement prior to the mitochondrial 
localization. The characterization of the glycan modification on the atypical N-X-C motif 
uncovered conserved cysteine residues that are important for ER exit of ABCB6. These 
cysteines are found in several other ABC family members and mutation in the conserved 
cysteine residue in ABCC8 results in the lack of its cell surface expression and is the 
genetic basis for hyperinsulinemic hypoglycemia in a patient.  
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5.1. ABCB6 Is a Homodimeric Mitochondrial Porphyrin Transporter 
 
 Substrates of ABC transporters are generally tested for one or more of the 
following characteristics: the binding to the transporters, the ability to stimulate ATPase 
activity, and the ATP-dependent uptake by the transporters. Substrate binding and the 
uptake assays are typically limited by an availability of radiolabeled compounds. In order 
to circumvent the use of radiolabeled hemin, our lab has previously utilized a pull-down 
assay using hemin conjugated to agarose to test the interaction between ABCG2 and 
heme [75]. ABCB6 binds to hemin-agarose specifically and the interaction can be 
disrupted by an addition of various porphyrins. Interestingly, only the compounds with 
tetrapyrrole ring were able to displace ABCB6 from hemin-agarose effectively. CPIII, an 
oxidized form of heme precursor, CPgenIII, was the most effective porphyrin tested in 
displacing ABCB6 from hemin-agarose. The commercially available CPIII is used 
throughout this study instead of the physiologically relevant CPgenIII, because CPgenIII 
is readily oxidized to CPIII in the atmosphere. Another heme precursor, PPIX and a plant 
porphyrin, PhA, also competed for binding of ABCB6 to hemin-agarose to a lesser 
extent. A monopyrrole, PBG, did not affect the interaction between ABCB6 and hemin-
agarose even though it is a heme precursor suggesting that ABCB6 recognizes a specific 
structure. Moreover, vitamin B12, which has a tetrapyrrole backbone as well as a bulky 
side chain, was not effective in displacing ABCB6 from hemin-agarose. These results 
show that ABCB6 recognizes anionic compounds with a tetrapyrrole ring, but the binding 
pocket cannot accommodate a bulky side chain.  
 
The substrate binding promotes ATP binding and a formation of NBD sandwich 
dimer, which results in stimulation of ATP hydrolysis. In order to measure ATPase 
activity of mitochondrial ABCB6, a cell line stably expressing non-functional Walker A 
mutant ABCB6 was established. The Walker A mutant ABCB6 contained glycine residue 
in place of conserved lysine residue the Walker A domain, a mutation that has been 
shown to disrupt ATP binding or hydrolysis in other ABC transporters [212, 213, 223]. 
An increase in the vanadate sensitive ATPase activity was observed in only the 
mitochondria prepared from K562 cells expressing wild type ABCB6-V5 but not in the 
Walker A mutant-V5. The modest increase may be attributed to the following factors: i) 
incomplete inhibition of F1Fo-ATPase in the mitochondria masked the much smaller 
ABCB6 ATPase activity and ii) both ATPase and transport acitivity of ABCB6 bearing a 
V5 tag was lower compared to the Flag-tagged ABCB6 for unknown reasons. Because 
the Walker A mutant cell line was established using the V5-tagged molecule, only the 
results from the V5-tagged ABCB6 are presented here. The Walker A mutant binds 
hemin as assessed by hemin-agarose pull-down assay, which was a useful feature when 
testing the uptake of hemin into mitochondria. Lack of ATP-dependent uptake of 
radiolabeled hemin into the Walker A mutant expressing mitochondria demonstrated that 
the assay measures the actual transport rather than hemin simply binding to the ABCB6 
at the membrane. Taken together, hemin meets all the criteria to be a substrate for 
ABCB6 and our results imply that other porphyrin are likely to be substrates as well. 
 
 ABCB6 is a half transporter with one MSD and one NBD; therefore, it must 
homo- or heterodimerize in order to reconstitute transport function. We hypothesized that 
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ABCB6 is likely to form a homodimer because there is no potential dimerizing partner on 
the mitochondrial outer membrane. Co-imunoprecipitation experiments using differently-
tagged ABCB6 show that it homodimerizes. The findings that the overexpression of 
ABCB6 alone was sufficient to observe transport activity, etc., also support the 
homodimerization of ABCB6. Recently, ABC transporters have been shown to contain 
multiple substrate binding sites/pockets that can accommodate structurally different 
compounds possibly at the same time [107, 115, 226]. A homodimeric half transporter 
ABCG2 has been proposed to contain multiple substrate binding pockets [54]. By 
creating a dimerization-deficient ABCB6, we wanted to test whether porphyrin binding 
was retained in a single molecule. This would provide some insights into how substrate 
binding sites are constituted in ABCB6. However, despite the generation of multiple 
mutants, we were unable to identify domain(s) that are important for dimerization, which 
may be an indication that the dimer is stabilized through multiple interaction sites.  
 
 
5.2. ABCB6 Accelerates Porphyrin Biosynthesis 
 
 Overexpression of ABCB6 increases a steady state PPIX levels in K562 cells. 
This effect was dependent on function of ABCB6 because K562 cells with the Walker A 
mutant ABCB6 showed no change in cellular PPIX levels compared to vector cells. We 
further demonstrated that de novo porphyrin biosynthesis was upregulated in cells 
expressing functional ABCB6. Heme biosynthesis takes place in two compartments 
requiring transmembrane movement of intermediates: ALA into the cytosol from 
mitochondria and CPgenIII into the mitochondrial intermembrane from the cytosol. The 
upregulation of porphyrin biosynthesis by ABCB6 and its function as the mitochondrial 
outer membrane transporter pumping porphyrins into the intermembrane space from the 
cystosol suggest that ABCB6 plays an important role in heme biosynthesis. Based on 
these results, we propose that ABCB6 is the elusive CPgenIII transporter in heme 
biosynthesis pathway, which had been an unanswered question in the field for a long 
time. CPgenIII readily associates with the membrane via its hydrophobic cyclic rings; 
however, the anionic side chains do not allow the transmembrane movement to occur 
easily. Indeed, previous studies show that the rate of simple diffusion of CPgenIII is not 
sufficient to support robust heme biosynthesis in differentiating erythroid cells and the 
presence of energy-dependent transport has been suggested [192, 193]. The movement of 
CPgenIII may represent yet another rate-limiting step in heme biosynthesis that ABCB6 
can overcome.  
 
 
5.3. ATP Binding Releases the Substrate from ABCB6 
 
 The transmembrane movement of compounds by ABC transporters is ATP-
dependent. Initial biochemical studies led to a model that ATP hydrolysis provided the 
power stroke for the transport [113]. However, structural data of isolated NBDs and 
recent biochemical studies suggest that formation of a NBD dimer induced by substrate 
and/or ATP binding is the power stroke for the substrate transport [97, 114]. This change 
in the conformation of NBD is then transmitted to MSD, which causes a sufficient 
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conformational change to release substrates on the other side of the membrane. Our 
results support the latter model, referred to as “ATP switch model,” in which binding of 
ATP induces a conformational change to a low affinity state for the substrate of ABCB6. 
Taking advantage of the affinity of ABCB6 for hemin-agarose, we demonstrated that 
addition of ATP at room temperature was sufficient to release ABCB6 from hemin-
agarose. Furthermore, non-hydrolyzable ATP anolog, AMPPNP, had a similar effect on 
the release of ABCB6 from hemin-agarose, although a higher concentration was required. 
Effects of mutating the conserved lysine residue in the Walker A domain varies among 
the ABC transporters. Walker A mutation in some ABC transporters results in a loss of 
ATP binding and subsequently ATP hydrolysis, whereas only the ATP hydrolysis is 
disrupted in others [213]. For ABCB6, loss of the conserved lysine residue resulted in a 
severely impaired ATP binding. Therefore, as expected, the Walker A mutant ABCB6 
remained bound to hemin-agarose after ATP or AMPPNP addition.  
 
Although structural data for mammalian ABC transporters are not available at this 
time, the structure of bacterial ABC transporter Sav1866 provided insights into the 
possible transport mechanism that is likely to be similar in the mammalian counterpart. 
The cytoplasmic loop from one subunit reaches over to contact the NBD from the other 
subunit and this interface may be important in transmitting information from NBDs to 
MSDs and vice versa [97]. The MSDs of nucleotide bound Sav1866 is forming outward 
wings, which suggests that it is in a position to release its substrate [97]. It has been 
shown that ATP hydrolysis and subsequent release of Pi and ADP disengages the NBD 
dimer suggesting that this process is involved in resetting the transporter to a high affinity 
state for the next transport cycle [114]. Our results show that ATP binding induces a 
sufficient conformational change and supports the transport mode described as the ATP 
switch model. However, understanding the precise mechanism requires further 
investigation. For some full transporters and heterodimeric half transporters, two NBDs 
are shown to be asymmetrical. The binding and hydrolysis of ATP require two NBDs 
because a functional ATPase site comprises of domains from the both NBDs [110]. For 
TAP1/TAP2 heterodimer, only one ATPase site contains consensus Walker B, histidine 
switch, and ABC signature motifs [111]. The consensus ATPase site is considered to 
provide the power stroke for peptide translocation by TAP1/TAP2. The combination of 
one consensus and one degenerate ATPase sites is seen in more than 20 ABC transporters 
[111], and therefore, the asymmetrical NBDs may reveal an important aspect of substrate 
transport. Whether a homodimer such as ABCB6 contains an asymmetry in its NBD 
dimer remains to be seen.      
 
 
5.4. ABCB6 Is Glycosylated and Contains a Disulfide-Bonded Loop That Acts as a 
Trafficking Signal 
 
 The initial identification of ABCB6 showed that it localized on the mitochondria 
[171]. Subsequently, we, and others showed its localization on the mitochondrial outer 
membrane [204, 250]. However, recent studies showed the localization of ABCB6 on 
other subcellular membranes such as the plasma membrane and the Golgi [250, 261]. 
Therefore, understanding ABCB6 intracellular trafficking may provide insights into how 
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ABCB6 reaches the mitochondrial outer membrane and other membranes. The objective 
was to study how ABCB6 trafficks in cells, as well as to identify if any signals for sorting 
or trafficking exist within ABCB6. The unexpected observation that ABCB6 is modified 
with Endo H resistant glycans, mitochondrial proteins are usually not glycosylated, 
indicated that ABCB6 trafficks to mitochondria via an unconventional way. Furthermore, 
the glycosylation site of ABCB6 consists of N-X-C instead of a typical N-X-S/T site. By 
characterizing the atypical glycosylation site, we demonstrate that the conserved cysteine 
residue, along with another cysteine residue in the N-terminus, plays an important role in 
ER exit of ABCB6. Interestingly, these cysteines are conserved in ABCC subfamily 
members that extrude the N-terminus into the ER lumen during maturation (long MRPs). 
This motif was functional in at least one of the long MRPs. Loss of the conserved 
cysteine in SUR1/ABCC8 results in a lack of cell surface expression and the lack of 
functional SUR1/ABCC8 is the genetic basis for a case of hyperinsulinemic 
hypoglycemia.  
 
 
5.4.1. Formation of Disulfide Bond in ABCB6 Acts as an ER Exit Signal 
 
 Post-translational modifications such as signal sequence cleavage, N-
glycosylation, and disulfide bond formation occur and are monitored in the ER to ensure 
that only properly modified proteins leave the ER. We found that when the cysteine 
residue (Cys8) in the glycosylation site of ABCB6 is substituted with serine, ABCB6 is 
still modified but with Endo H sensitive glycans. Glycans are Endo H sensitive when 
they are attached to proteins in the ER but acquire Endo H resistance after processing in 
Golgi. Therefore, Endo H sensitive glycans on C8S mutant indicated that it failed to exit 
the ER. The only other cysteine residue predicted to be exposed to the ER lumen is 
Cys26 and it is highly conserved among other species. The mutant ABCB6 where Cys26 
is substituted with serine or alanine also contained Endo H sensitive glycans. We also 
confirmed that these two conserved cysteine residues, Cys8 and Cys26, form an 
intramolecular disulfide bond that appears to be glycan-independent. Oxidative state of 
cysteine residues has been shown to regulate secretion of several proteins including IgM 
through a mechanism called “thiol retention” [234]. The cysteine residues monitored in 
thiol retention needs to oxidize through disulfide bond or by other means to exit the ER. 
ABCB6 does not appear to be regulated by thiol retention because mutation of both Cys8 
and Cys26 did not rescue the defective ER exit. Taken together, we propose that the 
disulfide-bonded loop at the N-terminus is a novel ER exit signal. 
 
 How the disulfide-bonded loop acts as an ER exit signal is yet to be determined. 
However, there are two possibilities: i) chaperones dissociate upon the formation of the 
loop as a result of loss of a binding site or ii) the loop formation creates a binding site for 
other chaperone proteins. It will be interesting to determine if there is a stable interaction 
between C8S or C26A mutant and ER resident proteins.  
 
 Many ABC transporters contain even number of TM helices and therefore have 
both N- and C-termini in the cytosol. However, there is a subset of ABC transporters in 
ABCC subfamily, which contain an additional five TM helices N-terminal to the 
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MSD1.The glycan modifications on the N-termini of these “long MRPs” indicate that 
their N-termini extrude into the ER lumen. The conserved cysteines identified in ABCB6 
are conserved in the long MRPs, ABCC1, C2, C3, C6, C8, and C9. The functionality of 
these cysteines are conserved at least in one of them, ABCC8/SUR1. Loss of one or both 
of the conserved cysteine residues results in the defective trafficking of SUR1/ABCC8. 
The mutation in the conserved cysteine residue in SUR1/ABCC8 was isolated from a 
patient with hyperinsulinemic hypoglycemia indicating that the failure to exit the ER is 
the cause of the disease. We have also observed some functional consequences to the loss 
of the conserved cysteine residues in ABCB6. Our preliminary results show that the 
unlike wild type ABCB6 expressing K562 cells, cells expressing C8S or C26A mutants 
have steady state PPIX levels that are comparable to the Walker A mutant cells.  
 
 
5.4.2. Intracellular Movement of ABCB6 
 
 The glycan modification on ABCB6 was unexpected because normally, 
mitochondrial proteins reach their destination after being fully translated in the cytosol. 
There is evidence for proteins moving from the ER to mitochondria. However, how 
proteins traffick from Golgi to mitochondria is poorly understood. Further investigation is 
required to identify how ABCB6 properly targets mitochondria. 
 
 The glycosylation at the very N-terminus revealed a unique topology of ABCB6. 
Half transporters typically contain six TM helices, thus positioning both N- and C-termini 
in the cytosol. Because the N-terminus of ABCB6 is in the ER lumen but its C-terminus 
is in the cytosol, ABCB6 is predicted to contain an odd number of TM helices. Also, the 
regions that contain consensus N-X-S/T sites are likely to reside in the cytosol due to the 
lack of glycosylation. Based on these criteria and the results from the glycosylation site 
insertion experiment, we favor the membrane topology model predicted by TMHMM, 
which has nine TM helices. Half transporters in ABCB subfamily, TAP1 and TAP2, have 
been shown to contain 10 and nine TM helices, respectively. These N-terminal extensions 
are important for interaction with tapasin. Perhaps, the additional three TM helices in 
ABCB6 play an important role in regulating its function or act as a binding site for other 
proteins.  
 
 
5.5. Conclusion 
 
 We have characterized the substrate, physiological role, transport mechanism, and 
trafficking signal of ABCB6. Since many ABC transporters are able to recognize 
structurally different compounds, many more substrates for ABCB6 may be identified in 
the future. It will be exciting to see if ABCB6 is involved in other biological processes. 
Moreover, tumor cells exhibit a high rate of heme biosynthesis, which is the basis for 
photodynamic therapy [190]. Therefore, whether ABCB6 is upregulated in these cells to 
facilitate heme biosynthesis will be of interest. The identification of the N-terminal 
disulfide-bonded loop formed by conserved cysteines has a broad implication for other 
ABC transporters as the motif is found in ABCC subfamily members. ABCC1 is one of 
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the three major drug transporters, and ABCC2, ABCC6, SUR1/ABCC8 and 
SUR2/ABCC9 are linked to human disorders (Dubin Johnson syndrome, PXE, FPHHI, 
and DCVT, respectively). Therefore, mutations in the conserved cysteine residues may 
result in a lack of cell surface expression of these transporters and, therefore, may lead to 
the above mentioned disorders. Furthermore, our results suggest that the cell surface 
expression pattern of these transporters may be altered in pathophysiological conditions 
that affect ER redox status. 
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